0000917520-25-000096 | 10-Q | XBRL Viewer | Integra Lifesciences Holdings Corp

Print Document

DERIVATIVE INSTRUMENTS - Schedule of Derivatives Not Designated as Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	$ (227)	$ 10	$ (1,904)	$ 385
Foreign currency forward contract
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	(170)	0	(1,865)	0
Foreign currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments not designated as hedging instruments, gain (loss), net	$ (57)	$ 10	$ (39)	$ 385

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CC
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E

+ Details

LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Lessee, Lease, Description [Line Items]
ROU assets	$ 138,187	$ 144,042
Current lease liabilities	13,826	14,540
Non-current lease liabilities	160,933	166,930
Total lease liabilities	$ 174,759	$ 181,470
Leased facilities
Lessee, Lease, Description [Line Items]
Weighted average remaining lease term (in years)	16 years	16 years 1 month 6 days
Weighted average discount rate	5.30%	5.40%
Leased vehicles
Lessee, Lease, Description [Line Items]
Weighted average remaining lease term (in years)	2 years 9 months 18 days	2 years 3 months 18 days
Weighted average discount rate	3.20%	2.80%

DERIVATIVE INSTRUMENTS

9 Months Ended

Sep. 30, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS

Interest Rate Hedging

The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company’s expected SOFR-indexed borrowings. Additionally, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to Term SOFR.

The Company held the following interest rate swaps as of September 30, 2025 and December 31, 2024 (dollar amounts in thousands):


	September 30, 2025		December 31, 2024							September 30, 2025		December 31, 2024
Hedged Item	Notional Amount				Designation Date	Effective Date	Termination Date	Fixed Interest Rate		Estimated Fair Value
										Asset (Liability)


1-month Term SOFR Loan	—		75,000		October 10, 2018	July 1, 2020	June 30, 2025	3.220	%	—		421
1-month Term SOFR Loan	—		75,000		October 10, 2018	July 1, 2020	June 30, 2025	3.199	%	—		502
1-month Term SOFR Loan	—		75,000		October 10, 2018	July 1, 2020	June 30, 2025	3.209	%	—		403
1-month Term SOFR Loan	100,000		100,000		December 18, 2018	December 30, 2022	December 31, 2027	2.885	%	1,200		3,406
1-month Term SOFR Loan	100,000		100,000		December 18, 2018	December 30, 2022	December 31, 2027	2.867	%	1,264		3,507
1-month Term SOFR Loan	575,000		575,000		December 15, 2020	July 31, 2025	December 31, 2027	1.415	%	25,507		34,537
1-month Term SOFR Loan	125,000		125,000		December 15, 2020	July 1, 2025	December 31, 2027	1.404	%	5,566		7,848
Basis Swap (1)	—		—		March 31, 2023	March 24, 2023	December 31, 2027	N/A		(1,864)		(1,829)
	$	900,000	$	1,125,000						$	31,673	$	48,795
(1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time

The interest rate swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in accumulated other comprehensive income (“AOCI”). For the three and nine months ended September 30, 2025, the Company recorded a gain of $1.3 million and a loss of $(9.6) million, respectively, in AOCI related to the change in fair value of the interest rate swaps. For the three and nine months ended September 30, 2024, the Company recorded a loss of $(17.1) million and a gain of $2.7 million, respectively, in AOCI related to the change in fair value of the interest rate swaps.

For the three and nine months ended September 30, 2025, the Company recorded gains of $4.6 million and $7.5 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. For the three and nine months ended September 30, 2024, the Company recorded gains of $4.1 million and $14.4 million, respectively, in the consolidated statements of operations related to the interest rate differential of the interest rate swaps. The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2025 within the next twelve months is $16.9 million.

The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in AOCI, net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.

Foreign Currency Hedging

From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.

The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.

Cross-Currency Rate Swaps

The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss francs (“CHFs”) and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in CHFs and receive U.S. dollars from the counterparties.

In December 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly principal payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.

In February 2025, the Company amended the CHF-denominated intercompany loan to extend the maturity to December 2030. Concurrently, the Company amended the cross-currency swap agreement, with a notional amount of $368.4 million, equivalent to CHF 328.1 million, to extend the maturity to December 2030.

The Company held the following cross-currency rate swaps as of September 30, 2025 and December 31, 2024 (dollar amounts in thousands):


					September 30, 2025	December 31, 2024	September 30, 2025		December 31, 2024
	Effective Date	Termination Date	Fixed Rate	Aggregate Notional Amount			Fair Value Asset (Liability)

Pay CHF	December 21, 2020	February 19, 2025	3.00%	CHF	—	328,136	—		(4,367)
Receive U.S.$			3.98%	$	—	368,362

Pay CHF	February 20, 2025	December 20, 2030	3.25%	CHF	310,887	—	(57,034)		—
Receive U.S.$			6.14%	$	348,997	—

Total							$	(57,034)	$	(4,367)

The cross-currency swaps designated as cash flow hedges are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2025, the Company recorded a gain of $9.0 million and a loss of $(40.5) million, respectively, in AOCI related to change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2024, the Company recorded a loss of $(16.6) million and a gain of $13.5 million, respectively, in AOCI related to change in fair value of the cross-currency swaps.

For the three and nine months ended September 30, 2025, the Company recorded a gain of $2.8 million and a loss of $(47.1) million, respectively, in other income, net related to the change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans. For the three and nine months ended September 30, 2024, the Company recorded a loss of $(23.2) million and a gain of $5.4 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans.

For the three and nine months ended September 30, 2025, the Company recorded gains of $2.3 million and $5.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2024, the Company recorded gains of $1.1 million and $3.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of September 30, 2025 within the next twelve months is $5.2 million.

Net Investment Hedges

The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business.

In February 2025, the Company entered into a cross-currency swap agreement with a notional amount of CHF 67.8 million equivalent to $75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.

On July 25, 2025, the Company entered into a cross-currency swap agreement with a notional amount of CHF 59.7 million, equivalent to $75.0 million, where the Company agreed with third-parties to sell CHF in exchange for U.S. dollars at a specified rate at the maturity of the contract. The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.

The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2025 and December 31, 2024, respectively (dollar amounts in thousands):


					September 30, 2025	December 31, 2024	September 30, 2025		December 31, 2024
	Effective Date	Termination Date	Fixed Rate	Aggregate Notional Amount			Fair Value Asset (Liability)

Pay EUR	October 3, 2018	September 30, 2025	—%	EUR	38,820	38,820	—		4,827
Receive U.S.$			2.19%	$	45,000	45,000

Pay CHF	May 26, 2022	December 16, 2028	—%	CHF	240,175	240,175	(58,351)		(27,951)
Receive U.S.$			1.94%	$	250,000	250,000

Pay CHF	November 17, 2023	December 17, 2029	—%	CHF	66,525	66,525	(10,982)		(3,248)
Receive U.S.$			2.54%	$	75,000	75,000

Pay CHF	May 6, 2024	December 18, 2030	—%	CHF	68,483	68,483	(12,761)		(4,741)
Receive U.S.$			2.74%	$	75,000	75,000

Pay CHF	February 21, 2025	December 15, 2031	—%	CHF	67,800	—	(9,602)		—
Receive U.S.$			3.24%	$	75,000	—

Pay CHF	July 25, 2025	December 15, 2032	—%	CHF	59,693	—	(2,478)		—
Receive U.S.$			2.66%	$	75,000	—

Total							$	(94,174)	$	(31,113)

The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI. For the three and nine months ended September 30, 2025, the Company recorded a gain of $5.0 million and a loss of $(54.4) million, respectively, in AOCI related to the change in fair value of the cross-currency swaps. For the three and nine months ended September 30, 2024, the Company recorded losses of $(21.1) million and $(0.4) million, respectively, in AOCI related to the change in fair value of the cross-currency swaps.

For the three and nine months ended September 30, 2025, the Company recorded gains of $3.4 million and $9.1 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps. For the three and nine months ended September 30, 2024, the Company recorded gains of $2.7 million and $7.4 million, respectively, in interest income included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2025 within the next twelve months is $11.4 million.

Foreign Currency Forward Contracts

The Company has entered into forward contracts designated as cash flow hedges for forecasted purchases in foreign currencies, primarily CHF denominated intercompany purchases. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs. These contracts typically settle at various dates within twelve months of execution. As of September 30, 2025 the notional amount of foreign currency forward contracts was CHF 12.3 million.

For the three and nine months ended September 30, 2025, the Company recorded a loss of $(0.2) million and a gain of $1.9 million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts. For the three and nine months ended September 30, 2024, the Company recorded a gain of $0.5 million and a loss of $(0.2) million, respectively, in AOCI related to the change in fair value of the foreign currency forward contracts.

For the three and nine months ended September 30, 2025, the Company recorded an immaterial loss and a loss of $(0.4) million, respectively, in other income and cost of goods sold included in the consolidated statements of operations related to the amortization of forward points and rate translation on the foreign currency forward contracts. For the three and nine months ended September 30, 2024, the Company recorded losses of $(0.1) million and $(0.3) million, respectively, in other income and cost of goods sold included in the consolidated statements of operations related to the amortization of forward points and rate translation on the foreign currency forward contracts.

Counterparty Credit Risk

The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.

Fair Value of Derivative Instruments

The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.

The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024:


	Fair Value as of
Location on Balance Sheet (1):	September 30, 2025		December 31, 2024
Dollars in thousands
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Interest rate swap	$	17,999	$	12,320
Cross-currency swap	3,518		—
Foreign currency forward contracts	309		—
Net Investment Hedges
Cross-currency swap	7,484		8,605
Other assets
Cash Flow Hedges
Interest rate swap	15,538		38,302




Total derivatives designated as hedges — Assets	$	44,848	$	59,227

Derivatives designated as hedges — Liabilities:
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap	$	1,144	$	684
Cross-currency swap	—		4,367
Foreign currency forward contracts	—		914
Net Investment Hedges
Cross-currency swap	6,670		210
Other liabilities
Cash Flow Hedges
Interest rate swap	720		1,145
Cross-currency swap	60,552		—

Net Investment Hedges
Cross-currency swap	94,988		39,507
Total derivatives designated as hedges — Liabilities	$	164,074	$	46,827

(1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.

The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three and nine months ended September 30, 2025 and 2024:


Dollars in thousands	Balance in AOCI Beginning of Quarter		Amount of Gain (Loss) Recognized in AOCI		Amount of Gain (Loss) Reclassified from AOCI into Earnings		Balance in AOCI End of Quarter		Location in Statements of Operations
Three Months Ended September 30, 2025
Cash Flow Hedges
Interest rate swap	$	35,051	$	1,253	$	4,629	$	31,675	Interest expense
Cross-currency swap	(14,767)		9,033		5,046		(10,780)		Other income, net
Foreign Currency Forward Contract	1,906		(162)		—		1,744		Cost of sales
Net Investment Hedges
Cross-currency swap	(96,173)		4,955		3,407		(94,625)		Interest income
	$	(73,983)	$	15,079	$	13,082	$	(71,986)
Three Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap	$	53,116	$	(17,133)	$	4,135	$	31,848	Interest expense
Cross-currency swap	(16,867)		(16,625)		(22,089)		(11,403)		Other income, net
Foreign Currency Forward Contract	$	(430)	$	474	$	(119)	$	163
Net Investment Hedges
Cross-currency swap	(29,466)		(21,051)		2,739		(53,256)		Interest income
	$	6,353	$	(54,335)	$	(15,334)	$	(32,648)

Dollars in thousands	Balance in AOCI Beginning of Year		Amount of Gain (Loss) Recognized in AOCI		Amount of Gain (Loss) Reclassified from AOCI into Earnings		Balance in AOCI End of Quarter		Location in Statements of Operations
Nine Months Ended September 30, 2025
Cash Flow Hedges
Interest rate swap	$	48,794	$	(9,630)	$	7,489	$	31,675	Interest expense
Cross-currency swap	(11,621)		(40,504)		(41,345)		(10,780)		Other income (expense), net
Foreign currency forward contract	(624)		1,941		(427)		1,744		Cost of sales
Net Investment Hedges
Cross-currency swap	(31,130)		(54,356)		9,139		(94,625)		Interest income
	$	5,419	$	(102,549)	$	(25,144)	$	(71,986)
Nine Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap	$	43,556	$	2,678	$	14,386	$	31,848	Interest expense
Cross-currency swap	(15,763)		13,505		9,145		(11,403)		Other income (expense), net
Foreign currency forward contract	—		$	(159)	$	(322)	163
Net Investment Hedges
Cross-currency swap	(45,498)		(364)		7,394		(53,256)		Interest income
	$	(17,705)	$	15,660	$	30,603	$	(32,648)

Derivative Instruments not Designated Hedges

From time to time, the Company enters into foreign currency forward contracts to mitigate risk from the fluctuations in foreign currency exchange rates associated with intercompany balances in Chinese yuan (“CNH”) CHF, and EUR. These contracts typically settle at various dates within twelve months of execution. As of September 30, 2025, the notional amounts totaled CNH 30.0 million and EUR 14.0 million, equivalent to $4.1 million, and $16.5 million, respectively.

In 2021, the Company entered into a foreign currency swap, with a notional amount of JPY 800.0 million, equivalent to $7.3 million, to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to JPY 400.0 million, equivalent to $3.6 million as of September 30, 2025.

The fair value of the foreign currency swaps not designated as hedges was $0.9 million and $1.7 million as of September 30, 2025 and December 31, 2024, respectively.

The following table summarizes the gains and losses on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:


Dollars in thousands	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Foreign currency forward contracts	(170)		—		(1,865)		—
Foreign currency swaps	(57)		$	10	(39)		$	385
Total	$	(227)	$	10	$	(1,904)	$	385

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 185
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-185

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 184
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-184

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 181
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-181

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 15
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480960/815-15-50-3

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 183
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-183

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4F
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/815/tableOfContent

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C

+ Details

DERIVATIVE INSTRUMENTS - Fair Value of Derivative Instruments By Balance Sheet Location (Details) - Designated as Hedging Instrument - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Assets	$ 44,848	$ 59,227
Total derivatives designated as hedges — Liabilities	164,074	46,827
Interest rate swap \| Cash Flow Hedges \| Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Assets	17,999	12,320
Interest rate swap \| Cash Flow Hedges \| Other assets
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Assets	15,538	38,302
Interest rate swap \| Cash Flow Hedges \| Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Liabilities	1,144	684
Interest rate swap \| Cash Flow Hedges \| Other liabilities
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Liabilities	720	1,145
Cross-currency swap \| Cash Flow Hedges \| Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Assets	3,518	0
Cross-currency swap \| Cash Flow Hedges \| Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Liabilities	0	4,367
Cross-currency swap \| Cash Flow Hedges \| Other liabilities
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Liabilities	60,552	0
Cross-currency swap \| Net Investment Hedges \| Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Assets	7,484	8,605
Cross-currency swap \| Net Investment Hedges \| Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Liabilities	6,670	210
Cross-currency swap \| Net Investment Hedges \| Other liabilities
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Liabilities	94,988	39,507
Foreign currency forward contract \| Cash Flow Hedges \| Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Assets	309	0
Foreign currency forward contract \| Cash Flow Hedges \| Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Total derivatives designated as hedges — Liabilities	$ 0	$ 914

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Income Statement [Abstract]
Total revenue, net	$ 402,062,000	$ 380,834,000	$ 1,200,320,000	$ 1,167,881,000
Costs and expenses:
Cost of goods sold	195,071,000	180,596,000	589,565,000	534,892,000
Research and development	22,456,000	27,435,000	74,181,000	84,167,000
Selling, general and administrative	169,046,000	177,193,000	530,433,000	538,463,000
Intangible asset amortization	3,728,000	3,760,000	11,186,000	17,575,000
Goodwill impairment charge	0	0	511,365,000	0
Total costs and expenses	390,301,000	388,984,000	1,716,730,000	1,175,097,000
Operating income (loss)	11,761,000	(8,150,000)	(516,410,000)	(7,216,000)
Interest income	4,982,000	5,049,000	14,112,000	15,147,000
Interest expense	(22,725,000)	(19,373,000)	(62,582,000)	(51,648,000)
Other (expense) income, net	(842,000)	2,112,000	(2,932,000)	2,939,000
Loss before income taxes	(6,824,000)	(20,362,000)	(567,812,000)	(40,778,000)
Benefit for income taxes	(1,420,000)	(9,667,000)	(53,042,000)	(14,399,000)
Net loss	$ (5,404,000)	$ (10,695,000)	$ (514,770,000)	$ (26,379,000)
Net loss per share
Basic (in dollars per share)	$ (0.07)	$ (0.14)	$ (6.72)	$ (0.34)
Diluted (in dollars per share)	$ (0.07)	$ (0.14)	$ (6.72)	$ (0.34)
Weighted average common shares outstanding (See Note 13):
Basic (in shares)	76,753	76,448	76,637	77,196
Diluted (in shares)	76,753	76,448	76,637	77,196
Comprehensive loss (See Note 14)	$ (6,472,000)	$ (16,823,000)	$ (519,174,000)	$ (36,126,000)

NET LOSS PER SHARE - Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Basic net loss per share:
Net loss	$ (5,404)	$ (484,073)	$ (25,293)	$ (10,695)	$ (12,402)	$ (3,281)	$ (514,770)	$ (26,379)
Weighted average common shares outstanding - Basic (in shares)	76,753			76,448			76,637	77,196
Basic net loss per common share (in dollars per share)	$ (0.07)			$ (0.14)			$ (6.72)	$ (0.34)
Diluted net loss per share:
Net loss	$ (5,404)	$ (484,073)	$ (25,293)	$ (10,695)	$ (12,402)	$ (3,281)	$ (514,770)	$ (26,379)
Weighted average common shares outstanding - Basic (in shares)	76,753			76,448			76,637	77,196
Effect of dilutive securities:
Stock options and restricted stock (in shares)	0			0			0	0
Weighted average common shares for diluted earnings per share (in shares)	76,753			76,448			76,637	77,196
Diluted net loss per common share (in dollars per share)	$ (0.07)			$ (0.14)			$ (6.72)	$ (0.34)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

DERIVATIVE INSTRUMENTS - Narrative (Details) $ in Thousands, € in Millions, ¥ in Millions, ¥ in Millions, SFr in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2025 CHF (SFr)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 CHF (SFr)	Sep. 30, 2025 EUR (€)	Sep. 30, 2025 CNY (¥)	Sep. 30, 2025 JPY (¥)	Jul. 25, 2025 USD ($)	Jul. 25, 2025 CHF (SFr)	Feb. 28, 2025 USD ($)	Feb. 28, 2025 CHF (SFr)	Dec. 31, 2024 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 JPY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 CHF (SFr)
Derivative [Line Items]
Gain (loss) estimated to be reclassified to earnings during next twelve months	$ 11,400		$ 11,400
Designated as Hedging Instrument
Derivative [Line Items]
Gain (loss) recorded in AOCI, change in fair value	15,079	$ (54,335)	(102,549)		$ 15,660
Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative assets (liabilities), at fair value, net	900		900											$ 1,700
Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Current notional amount	900,000		900,000											$ 1,125,000
Interest rate swaps
Derivative [Line Items]
Gain (loss) estimated to be reclassified to earnings during next twelve months	16,900		16,900
Interest rate swaps \| Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Gain (loss) recognized in accumulated other comprehensive income	1,300	(17,100)	(9,600)		2,700
Gain (loss) reclassified into other income	4,600	4,100	7,500		14,400
Gain (loss) recorded in AOCI, change in fair value	1,253	(17,133)	(9,630)		2,678
Cross-currency swap
Derivative [Line Items]
Gain (loss) reclassified into other income	2,300	1,100	5,700		3,700
Gain (loss) estimated to be reclassified to earnings during next twelve months	5,200		5,200
Current notional amount												$ 368,400	SFr 328.1				$ 471,600	SFr 420.1
Intercompany loan quarterly payments \| SFr				SFr 5.8
Cross-currency swap \| Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Gain (loss) reclassified into other income	2,800	(23,200)	(47,100)		5,400
Gain (loss) recorded in AOCI, change in fair value	9,033	(16,625)	(40,504)		13,505
Cross-currency swap \| Cash Flow Hedges \| Designated as Hedging Instrument \| Other income, net
Derivative [Line Items]
Gain (loss) recorded in AOCI, change in fair value	9,000	(16,600)	(40,500)		13,500
Cross-currency swap \| Net Investment Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Gain (loss) reclassified into other income	3,400	2,700	9,100		7,400
Gain (loss) recorded in AOCI, change in fair value	4,955	(21,051)	(54,356)		(364)
Cross-currency swap \| Net Investment Hedges \| Designated as Hedging Instrument \| Interest income
Derivative [Line Items]
Gain (loss) recorded in AOCI, change in fair value	5,000	(21,100)	(54,400)		(400)
Foreign currency swaps \| Not Designated as Hedging Instrument
Derivative [Line Items]
Current notional amount	3,600		3,600						¥ 400.0						$ 7,300	¥ 800.0
Foreign currency swaps \| Net Investment Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Current notional amount										$ 75,000	SFr 59.7	$ 75,000	SFr 67.8
Foreign currency forward contract \| Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Current notional amount \| SFr						SFr 12.3
Gain (loss) recorded in AOCI, change in fair value	(162)	474	1,941		(159)
Foreign currency forward contract \| Cash Flow Hedges \| Designated as Hedging Instrument \| Other income, net
Derivative [Line Items]
Gain (loss) recorded in AOCI, change in fair value	0	(100)	(400)		(300)
Foreign currency forward contract \| Cash Flow Hedges \| Designated as Hedging Instrument \| Cost of sales
Derivative [Line Items]
Gain (loss) recorded in AOCI, change in fair value	(200)	$ 500	1,900		$ (200)
CNH Exchange Forward \| Not Designated as Hedging Instrument
Derivative [Line Items]
Current notional amount	4,100		4,100					¥ 30.0
EUR Exchange Forward \| Not Designated as Hedging Instrument
Derivative [Line Items]
Current notional amount	$ 16,500		$ 16,500				€ 14.0

STOCK-BASED COMPENSATION	9 Months Ended
STOCK-BASED COMPENSATION	Sep. 30, 2025
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION As of September 30, 2025, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”). Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change-in-control provisions within their grant agreements. The Company values stock option grants using the binomial distribution model. Restricted stock issued under the 2003 Plan vests over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions. Stock Options As of September 30, 2025, there were approximately $4.9 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 395,252 stock options granted during the nine months ended September 30, 2025. For the nine months ended September 30, 2025, the weighted average grant date fair value for stock options granted was $10.77 per option. Awards of Restricted Stock and Performance Stock Performance stock and restricted stock awards generally have requisite service periods of three years, except in certain instances that result in accelerated vesting due to death, disability, retirement age provision or change-in-control provisions in their grant agreements. Performance stock units are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses the fair value of restricted stock awards on a straight-line basis over the requisite service period. As of September 30, 2025, there was approximately $33.0 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 1,012,799 restricted stock awards and 395,781 performance stock awards during the nine months ended September 30, 2025. For the nine months ended September 30, 2025, the weighted average grant date fair value for restricted stock awards and performance stock units granted was $21.09 and $23.95 per award, respectively. The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.

REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Changes in Contract Assets and Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2025 USD ($)
Contract Asset
Contract asset, Beginning of period	$ 6,146
Transferred to trade receivables from contract asset included in beginning of the year contract asset	(6,146)
Contract asset, net of transferred to trade receivables on contracts during the period	4,928
Contract asset, End of period	4,928
Contract Liability
Contract liability, Beginning of period	19,669
Recognition of revenue included in beginning of year contract liability	(8,452)
Contract liability, net of revenue recognized on contracts during the period	11,008
Foreign currency translation	123
Contract liability, End of period	$ 22,348

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Net sales and profit by each reportable segment for the three and nine months ended September 30, 2025 and 2024 are as follows:


	Three Months Ended September 30, 2025								Nine Months Ended September 30, 2025
Dollars in thousands	Codman Specialty Surgical		Tissue Technologies		Corporate and Other		Total		Codman Specialty Surgical		Tissue Technologies		Corporate and Other		Total
Total revenue, net	$	292,583	$	109,479	$	—	$	402,062	$	877,204	$	323,116	$	—	$	1,200,320

Cost of goods sold	93,289		42,668		59,114		195,071		288,070		138,499		162,996		589,565
Research and development	6,632		4,189		11,635		22,456		22,276		12,243		39,662		74,181
Selling, general & administrative	62,433		35,478		71,135		169,046		201,309		110,283		218,841		530,433
Intangible asset amortization	—		—		3,728		3,728		—		—		11,186		11,186
Goodwill impairment	—		—		—		—		388,106		123,259		—		511,365
Total cost and expenses	162,354		82,335		145,612		390,301		899,761		384,284		432,685		1,716,730

Operating income (loss)	$	130,229	$	27,144	$	(145,612)	11,761		$	(22,557)	$	(61,168)	$	(432,685)	(516,410)
Interest income							4,982								14,112
Interest expense							(22,725)								(62,582)
Other income, net							(842)								(2,932)
Loss before income taxes							$	(6,824)							$	(567,812)


	Three Months Ended September 30, 2024								Nine Months Ended September 30, 2024
Dollars in thousands	Codman Specialty Surgical		Tissue Technologies		Corporate and Other		Total		Codman Specialty Surgical		Tissue Technologies		Corporate and Other		Total
Total revenue, net	$	270,782	$	110,052	$	—	$	380,834	$	828,977	$	338,904	$	—	$	1,167,881

Cost of goods sold	95,829		40,529		44,238		180,596		281,443		119,512		133,937		534,892
Research and development	8,548		4,506		14,381		27,435		21,880		13,858		48,429		84,167
Selling, general & administrative	65,867		36,535		74,791		177,193		157,483		109,199		271,781		538,463
Intangible asset amortization	—		—		3,760		3,760		—		—		17,575		17,575

Total cost and expenses	170,244		81,570		137,170		388,984		460,806		242,569		471,722		1,175,097

Operating income (loss)	$	100,538	$	28,482	$	(137,170)	(8,150)		$	368,171	$	96,335	$	(471,722)	(7,216)
Interest income							5,049								15,147
Interest expense							(19,373)								(51,648)
Other income, net							2,112								2,939
Loss before income taxes							$	(20,362)							$	(40,778)

Schedule of Geographic Revenue, by Area

Total revenue by major geographic area consisted of the following:


	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in thousands	2025		2024		2025		2024
United States	$	295,846	$	290,192	$	884,371	$	856,646
Europe	42,893		34,368		120,813		116,653
Asia Pacific	42,680		37,052		135,517		132,548
Rest of World	20,643		19,222		59,619		62,034
Total Revenues	$	402,062	$	380,834	$	1,200,320	$	1,167,881

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 232,186	$ 246,375
Short-term investments	35,693	27,192
Trade accounts receivable, net of allowances of $5,637 and $6,917	262,160	272,370
Inventories, net	489,106	429,090
Prepaid expenses	94,111	77,001
Other current assets	30,326	29,653
Total current assets	1,143,582	1,081,681
Property, plant and equipment, net	437,367	405,723
Right of use asset - operating leases	138,187	144,042
Intangible assets, net	1,160,145	1,207,588
Goodwill	615,199	1,096,952
Deferred tax assets, net	109,728	34,923
Other assets	42,244	66,515
Total assets	3,646,452	4,037,424
Current liabilities:
Current portion of borrowings under senior credit facility	38,750	33,906
Current portion of lease liability - operating leases	13,826	14,540
Convertible securities	0	573,170
Accounts payable, trade	92,305	82,502
Contract liabilities	11,326	10,483
Accrued compensation	74,987	85,617
Accrued expenses and other current liabilities	132,860	121,908
Total current liabilities	364,054	922,126
Long-term borrowings under senior credit facility	1,708,851	1,087,917
Long-term borrowings under securitization facility	83,500	108,100
Lease liability - operating leases	160,933	166,930
Deferred tax liabilities	58,285	60,833
Other liabilities	233,255	146,238
Total liabilities	2,608,878	2,492,144
Stockholders’ equity:
Preferred stock; no par value; 15,000 authorized shares; none outstanding	0	0
Common stock; $0.01 par value; 240,000 authorized shares; 92,251 and 91,610 issued at September 30, 2025 and December 31, 2024, respectively	923	916
Additional paid-in capital	1,333,506	1,323,431
Treasury stock, at cost; 14,416 shares and 14,445 shares at September 30, 2025 and December 31, 2024, respectively	(690,025)	(691,411)
Accumulated other comprehensive loss	(31,975)	(27,571)
Retained earnings	425,145	939,915
Total stockholders’ equity	1,037,574	1,545,280
Total liabilities and stockholders’ equity	$ 3,646,452	$ 4,037,424

SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) product in Thousands	9 Months Ended
	Sep. 30, 2025 Segment product
Segment Reporting Information [Line Items]
Number of reportable segments \| Segment	2
Codman Specialty Surgical
Segment Reporting Information [Line Items]
Number of products offered (more than) \| product	40

DEBT - Narrative (Details) - USD ($)				9 Months Ended
DEBT - Narrative (Details) - USD ($)	Aug. 15, 2025	Jun. 06, 2025	Feb. 07, 2020	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024	Dec. 15, 2023	Mar. 24, 2023
Debt Instrument [Line Items]
Current portion of borrowings under senior credit facility				$ 38,750,000		$ 33,906,000
Interest payments, remainder of fiscal year				11,800,000
Interest payments, year one				45,500,000
Interest payments, year two				42,800,000
Interest payments, year three				9,300,000
Repayments of convertible debt				574,983,000	$ 0
Securitization program outstanding borrowings, maximum limit				$ 150,000,000.0
Issuance costs associated with amendment							$ 300,000
Securitization facility, agreement term (in years)							3 years
Remaining unamortized issuance costs							$ 100,000
Security facility, weighted average interest rate				5.20%		5.40%
Carrying Value
Debt Instrument [Line Items]
Debt issuance costs, net				$ 3,649,000		$ 5,476,000
Debt instrument, gross, fair value disclosure				1,834,750,000		1,808,569,000
Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure				1,827,599,000		1,772,712,000
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity								$ 1,300,000,000
Standby Letters of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity								60,000,000
Swingline Loans
Debt Instrument [Line Items]
Maximum borrowing capacity								60,000,000
Senior Credit Facility
Debt Instrument [Line Items]
Debt issuance costs, net		$ 3,900,000
Maximum borrowing capacity								2,100,000,000
Senior Credit Facility \| Revolving Credit Facility \| Level 2 \| Carrying Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure				1,015,000,000		365,000,000
Senior Credit Facility \| Revolving Credit Facility \| Level 2 \| Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure				1,011,573,000		360,144,000
Senior Credit Facility \| Standby Letters of Credit
Debt Instrument [Line Items]
Letters of credit outstanding				3,000,000.0		$ 1,700,000
Line of credit facility outstanding				$ 0
Senior Credit Facility \| Covenant Relief Period \| Minimum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage		0.15%
Senior Credit Facility \| Covenant Relief Period \| Maximum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage		0.33%
Senior Credit Facility \| Thereafter Covenant Relief Period \| Minimum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage		0.15%
Senior Credit Facility \| Thereafter Covenant Relief Period \| Maximum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage		0.30%
Senior Credit Facility \| Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Debt instrument, basis spread adjustment on variable rate		0.10%
Interest rates available to the company at its option		1.00%
Senior Credit Facility \| Secured Overnight Financing Rate (SOFR) \| Covenant Relief Period \| Minimum
Debt Instrument [Line Items]
Interest rates available to the company at its option		1.00%
Senior Credit Facility \| Secured Overnight Financing Rate (SOFR) \| Covenant Relief Period \| Maximum
Debt Instrument [Line Items]
Interest rates available to the company at its option		2.13%
Senior Credit Facility \| Secured Overnight Financing Rate (SOFR) \| Thereafter Covenant Relief Period \| Minimum
Debt Instrument [Line Items]
Interest rates available to the company at its option		1.00%
Senior Credit Facility \| Secured Overnight Financing Rate (SOFR) \| Thereafter Covenant Relief Period \| Maximum
Debt Instrument [Line Items]
Interest rates available to the company at its option		1.75%
Senior Credit Facility \| Overnight Federal Funds
Debt Instrument [Line Items]
Interest rates available to the company at its option		0.50%
Term Loan Facility \| Secured Debt
Debt Instrument [Line Items]
Maximum borrowing capacity								$ 775,000,000
Weighted average interest rate on debt				6.40%		6.00%
Current portion of borrowings under senior credit facility				$ 38,800,000		$ 33,900,000
Term Loan Facility \| Secured Debt \| Level 2 \| Carrying Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure				736,250,000		760,469,000
Term Loan Facility \| Secured Debt \| Level 2 \| Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure				733,980,000		751,143,000
2025 Notes \| Convertible Debt
Debt Instrument [Line Items]
Debt, interest rate			0.50%
Repayments of convertible debt	$ 575,000,000.0
Shares issued to settle convertible senior notes (in shares)	0
Debt instrument, convertible, conversion price (in dollars per share)			$ 73.67
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 113.34
2025 Notes \| Convertible Debt \| Call Option
Debt Instrument [Line Items]
Payments for option index to issuers equity			$ 104,200,000
Proceeds from issuance of warrants			$ 44,500,000
Securitization \| Level 2 \| Carrying Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure				83,500,000		108,100,000
Securitization \| Level 2 \| Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure				$ 82,046,000		$ 105,831,000

TREASURY STOCK	9 Months Ended
TREASURY STOCK	Sep. 30, 2025
Equity [Abstract]
TREASURY STOCK	TREASURY STOCK As of September 30, 2025 and December 31, 2024, the company held 14.4 million shares of treasury stock outstanding with a cost of $690.0 million and $691.4 million, respectively, at a weighted average cost per share of $47.86 for both periods. In 2024, the Company entered into a $50 million accelerated share repurchase (“the 2024 ASR”) and received 1.3 million shares of common stock at inception of the 2024 ASR, which represented approximately 70% of the expected total shares under the 2024 ASR. The early exercise provision was exercised by the 2024 ASR counterparty. The Company received an additional 0.4 million shares determined using the volume-weighted average price of the Company’s common stock during the term of the 2024 ASR. On July 18, 2023, the Board of Directors authorized a new $225 million share repurchase program. As of September 30, 2025, $50 million remained authorized. The program, which was authorized in July 2023 and expires on December 31, 2025, allows the Company to repurchase its shares opportunistically from time to time. The Company may utilize various methods to effect any repurchases, including open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, including accelerated share repurchases, or a combination of the foregoing, some of which may be effected through Rule 10b5-1 plans. The price and timing of any future purchases under the share repurchase program will depend on factors such as levels of cash generation from operations, the volume of stock option exercises by employees, cash requirements for acquisitions, dividends, economic and market conditions and stock price, and such repurchases may be discontinued at any time.

DEBT - Schedule of Carrying Amounts and Estimated Fair Values of Debt Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Jun. 06, 2025	Dec. 31, 2024
Carrying Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	$ 1,834,750		$ 1,808,569
Debt issuance costs	(3,649)		(5,476)
Total debt	1,831,101		1,803,093
Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	1,827,599		1,772,712
Total debt	1,827,599		1,772,712
Senior Credit Facility
Debt Instrument [Line Items]
Debt issuance costs		$ (3,900)
2025 Notes \| Level 1 \| Carrying Value \| Convertible Debt
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	0		575,000
2025 Notes \| Level 1 \| Estimated Fair Value \| Convertible Debt
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	0		555,594
Securitization \| Level 2 \| Carrying Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	83,500		108,100
Securitization \| Level 2 \| Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	82,046		105,831
Secured Debt \| Term Loan Facility \| Level 2 \| Carrying Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	736,250		760,469
Secured Debt \| Term Loan Facility \| Level 2 \| Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	733,980		751,143
Revolving Credit Facility \| Senior Credit Facility \| Level 2 \| Carrying Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	1,015,000		365,000
Revolving Credit Facility \| Senior Credit Facility \| Level 2 \| Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument, gross, fair value disclosure	$ 1,011,573		$ 360,144

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2025

Earnings Per Share [Abstract]

NET LOSS PER SHARE

Basic and diluted net loss per share was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in thousands, except per share amounts	2025		2024		2025		2024
Basic net loss per share:
Net loss	$	(5,404)	$	(10,695)	$	(514,770)	$	(26,379)
Weighted average common shares outstanding	76,753		76,448		76,637		77,196

Basic net loss per common share	$	(0.07)	$	(0.14)	$	(6.72)	$	(0.34)

Diluted net loss per share:
Net loss	$	(5,404)	$	(10,695)	$	(514,770)	$	(26,379)

Weighted average common shares outstanding — Basic	76,753		76,448		76,637		77,196
Effect of dilutive securities:
Stock options and restricted stock	—		—		—		—
Weighted average common shares for diluted earnings per share	76,753		76,448		76,637		77,196

Diluted net loss per common share	$	(0.07)	$	(0.14)	$	(6.72)	$	(0.34)

Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, non-vested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.

Common stock of approximately 1.5 million and 1.3 million shares at September 30, 2025 and 2024, respectively, were not included in the computation of diluted net loss per share because their effect would have been anti-dilutive.

COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2025

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2025 and September 30, 2024 is as follows (in thousands):


Nine Months Ended September 30, 2025	Contingent Consideration Liability Related to Acquisition of:
	Arkis (1)		Derma Sciences (2)		ACell (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2025	$	12,968	$	2,686	$	3	54,000		69,657
Payment	(5,000)		—		—		(18,075)		(23,075)
Change in fair value of contingent consideration liabilities	(1,770)		(2,349)		—		(10,525)		(14,644)
Balance as of September 30, 2025	6,198		337		3		25,400		31,938

Short-Term - Accrued expenses and other liabilities	$	—	$	—	$	3	$	25,400	$	25,403
Long-Term - Other liabilities	6,198		337		—		—		6,535
Total	6,198		337		3		25,400		31,938


Nine Months Ended September 30, 2024	Contingent Consideration Liability Related to Acquisition of:
	Arkis (1)		Derma Sciences (2)		ACell (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2024	$	15,755	$	2,557	$	300	$	68,700	87,312
Payment							(12,400)		(12,400)
Change in fair value of contingent consideration liabilities	(3,019)		137		—		3,100		218
Balance as of September 30, 2024	$	12,736	$	2,694	$	300	$	59,400	75,130

Short-Term - Accrued expenses and other liabilities	$	8,320	$	—	$	—	$	19,600	$	27,920
Long-Term - Other liabilities	4,416		2,694		300		39,800		47,210
Total	12,736		2,694		300		59,400		75,130

(1) Location in financial statements: Research and development

(2) Location in financial statements: Selling, general and administrative

ACCUMULATED OTHER COMPREHENSIVE LOSS

9 Months Ended

Sep. 30, 2025

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

Comprehensive loss for the three and nine months ended September 30, 2025 and 2024:


	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in thousands	2025		2024		2025		2024
Net loss	$	(5,404)	$	(10,695)	$	(514,770)	$	(26,379)
Foreign currency translation adjustment	(1,701)		5,386		6,484		(2,558)
Change in unrealized (gain) loss on derivatives, net of tax	800		(11,044)		(10,405)		(6,714)
Pension liability adjustment, net of tax	(167)		(470)		(483)		(475)
Comprehensive loss, net	$	(6,472)	$	(16,823)	$	(519,174)	$	(36,126)

Changes in accumulated other comprehensive loss by component between December 31, 2024 and September 30, 2025 are presented in the table below, net of tax:


Dollars in thousands	Gains and Losses on Derivatives		Defined Benefit Pension Items		Foreign Currency Items		Total
Balance at January 1, 2025	$	26,612	$	4,028	$	(58,211)	$	(27,571)
Other comprehensive (loss) gain	(41,147)				13,510		(27,637)
Less: Amounts reclassified from accumulated other comprehensive income, net	(30,742)		483		7,026		(23,233)
Net current-period other comprehensive (loss) gain	(10,405)		(483)		6,484		(4,404)
Balance at September 30, 2025	$	16,207	$	3,545	$	(51,727)	$	(31,975)

For the nine months ended September 30, 2025, the Company reclassified losses of $(35.7) million and $(0.3) million from AOCI to other income and cost of goods sold, respectively. Additionally, the Company reclassified a gain of $12.8 million from AOCI to interest income.

NET LOSS PER SHARE - Narrative (Details) - shares shares in Millions	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Earnings Per Share [Abstract]
Shares excluded from computation as their effect would be antidilutive (in shares)	1.5	1.3

BASIS OF PRESENTATION - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 232,186	$ 246,375
Short-term investments	$ 35,693	$ 27,192

ACQUISITIONS AND DIVESTITURES

9 Months Ended

Sep. 30, 2025

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

ACQUISITIONS AND DIVESTITURES

Acquisition of Durepair®

On October 2, 2024, the Company completed the acquisition of the product rights for Durepair Regeneration Matrix (“Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total consideration of $45.0 million. The Company made cash payments of $10.0 million upon the closing of the acquisition in October 2024, $15.0 million on the first anniversary of the acquisition in October 2025, and will make an additional cash payment of $20.0 million upon the second anniversary of the acquisition in October 2026. The additional cash payments in October 2025 and October 2026 are included at present value in accrued expenses and other current liabilities and other liabilities, respectively, as of September 30, 2025.

The acquisition of the product rights for Durepair, which consist of certain patents and trademarks, regulatory approvals, and other records, has been accounted for as an asset acquisition in accordance with FASB Topic 805, Business Combinations (“ASC 805”) as the acquisition does not include an assembled workforce and substantially all of the fair value of the assets acquired is concentrated in a single identifiable intangible asset.

Acquisition of Acclarent, Inc.

On April 1, 2024, the Company completed the acquisition of all of the outstanding capital stock of Acclarent, Inc. (“Acclarent”), a developer and marketer of medical devices used in ear, nose, throat (“ENT”) procedures, from Ethicon, Inc., a subsidiary of Johnson & Johnson, for approximately $282.0 million in cash, subject to customary adjustments set forth in the purchase agreement related to working capital balances transferred to the Company. In the second half of 2024, the Company finalized and settled the working capital adjustment in the amount of $4.2 million, which resulted in a reduction to goodwill and also recognized a measurement period adjustment to recognize deferred tax liabilities of $1.1 million with a corresponding increase to goodwill as a result of a change to the estimated deferred tax rate applied and the book-to-tax difference associated with fixed assets acquired.

The addition of Acclarent’s ENT product portfolio, including sinus balloon dilation, eustachian tube balloon dilation, and surgical navigation systems technologies, and dedicated salesforce enhanced the Company’s position in the ENT specialty device market. Acclarent’s results of operations have been reported in the Company’s Codman Specialty Surgical reportable segment from the date of acquisition.

Assets Acquired and Liabilities Assumed at Fair Value

The Acclarent acquisition has been accounted for using the acquisition method of accounting in accordance with ASC 805. This method requires that assets acquired and liabilities assumed in a business combination are recognized at their fair values as of the acquisition date.

The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:


Dollars in thousands	Estimated Fair Value		Estimated Useful Life
Current assets:
Cash	$	—
Trade accounts receivable, net of allowances of $3,885	23,716
Inventories, net	20,294
Prepaid expenses	273
Other current assets	476
Total current assets	$	44,759
Property, plant and equipment, net	7,716
Right of use asset - operating leases	989
Intangible assets, net
Completed technology	202,000		12 years
Trademarks/brand names	3,000		5 years
All other	17,000		4 years
Goodwill	62,482
Deferred tax assets	6,895
Total assets acquired	$	344,841

Current liabilities:
Accounts payable, trade	3,989
Contract liabilities	3,984
Accrued compensation	1,037
Accrued expenses and other current liabilities	2,278
Current portion of lease liability - operating leases	365
Total current liabilities	$	11,653
Lease liability - operating leases	624
Deferred tax liabilities	54,753
Total liabilities assumed	67,030

Net assets acquired	$	277,811

The carrying value of trade accounts receivable, prepaid expenses, other current assets, accounts payable, contract liabilities, accrued compensation, accrued expenses and other current liabilities, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition.

Intangible Assets

The estimated fair value of the intangible assets acquired was determined using the multi-period, excess earnings method of the income approach, which estimates value based on the present value of future economic benefits attributable to the intangible assets. The significant assumptions used in developing the valuation included the estimated annual net cash flows including application of revenue growth rates, cost of sales, the discount rate that appropriately reflects the risk inherent in each future cash flow stream, obsolescence rate, and an assessment of the asset’s life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. The intangible assets acquired have a weighted average useful life of 11 years.

The Company used a discount rate of 12.2% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.

Goodwill

Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected synergies of the combined company and assembled workforce. Goodwill has been allocated to the Codman Specialty Surgical segment, as shown in Note 5. Goodwill and Other Intangible Assets. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.

Deferred Tax Liabilities

Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) liability	Sep. 30, 2024 USD ($)	Dec. 31, 2022 USD ($) payment	Dec. 31, 2019 USD ($)
Loss Contingencies [Line Items]
Payment for contingent consideration				$ 16,451	$ 11,923
Arkis
Loss Contingencies [Line Items]
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)							$ 25,500
Contingent consideration							13,100
Arkis \| Development Milestones
Loss Contingencies [Line Items]
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)							10,000
Payment for contingent consideration		$ 5,000
Arkis \| Commercial Sales Milestones
Loss Contingencies [Line Items]
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)							$ 15,500
Derma Sciences
Loss Contingencies [Line Items]
Number of liabilities \| liability				1
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)				$ 3,000
Derma Sciences \| BioD Earnout Payments and Medihoney Earnout Payments
Loss Contingencies [Line Items]
Payment for contingent consideration				$ 33,300
ACell, Inc.
Loss Contingencies [Line Items]
Number of liabilities \| liability				1
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)				$ 23,900
ACell, Inc. \| Revenue-Based Performance Milestones In 2023
Loss Contingencies [Line Items]
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)				$ 100,000
Surgical Innovation Associates, Inc.
Loss Contingencies [Line Items]
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)						$ 90,000
Business acquisition, number of payments \| payment						2
Surgical Innovation Associates, Inc. \| Revenue Based Performance Milestones
Loss Contingencies [Line Items]
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)						$ 32,600
Payment for contingent consideration	$ 18,100		$ 12,400
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)						50,000
Surgical Innovation Associates, Inc. \| FDA Approval Of Premarket Approval
Loss Contingencies [Line Items]
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)						25,000
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)						$ 40,000

REVENUES FROM CONTRACTS WITH CUSTOMERS - Schedule of Revenues Disaggregated by Major Source (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Disaggregation of Revenue [Line Items]
Total revenue	$ 402,062	$ 380,834	$ 1,200,320	$ 1,167,881
Codman Specialty Surgical
Disaggregation of Revenue [Line Items]
Total revenue	292,583	270,782	877,204	828,977
Codman Specialty Surgical \| Neurosurgery
Disaggregation of Revenue [Line Items]
Total revenue	201,563	175,956	601,466	583,726
Codman Specialty Surgical \| Instruments
Disaggregation of Revenue [Line Items]
Total revenue	50,151	54,238	154,181	153,148
Codman Specialty Surgical \| ENT
Disaggregation of Revenue [Line Items]
Total revenue	40,869	40,588	121,557	92,103
Tissue Technologies
Disaggregation of Revenue [Line Items]
Total revenue	109,479	110,052	323,116	338,904
Tissue Technologies \| Wound Reconstruction and Care
Disaggregation of Revenue [Line Items]
Total revenue	83,988	80,460	243,514	249,032
Tissue Technologies \| Private Label
Disaggregation of Revenue [Line Items]
Total revenue	$ 25,491	$ 29,592	$ 79,602	$ 89,872

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2025
Effective Income Tax Rate Reconciliation [Line Items]
Effective income tax rate	20.80%	47.50%	9.30%	35.30%
Income tax benefit from prior year income taxes				$ 1.9
Forecast
Effective Income Tax Rate Reconciliation [Line Items]
Tax adjustments, settlements, and unusual provisions					$ 4.4

DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments (Details) - Cash Flow Hedges - Designated as Hedging Instrument - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Derivative [Line Items]
Notional Amount	$ 900,000	$ 1,125,000
Estimated Fair Value	31,673	48,795
Interest Rate Swap Designated October 10, 2018 Tranche 1
Derivative [Line Items]
Notional Amount	$ 0	75,000
Fixed Interest Rate	3.22%
Estimated Fair Value	$ 0	421
Interest Rate Swap Designated October 10, 2018 Tranche 2
Derivative [Line Items]
Notional Amount	$ 0	75,000
Fixed Interest Rate	3.199%
Estimated Fair Value	$ 0	502
Interest Rate Swap Designated October 10, 2018 Tranche 3
Derivative [Line Items]
Notional Amount	$ 0	75,000
Fixed Interest Rate	3.209%
Estimated Fair Value	$ 0	403
Interest Rate Swap Designated December 18, 2018 Tranche 1
Derivative [Line Items]
Notional Amount	$ 100,000	100,000
Fixed Interest Rate	2.885%
Estimated Fair Value	$ 1,200	3,406
Interest Rate Swap Designated December 18, 2018 Tranche 2
Derivative [Line Items]
Notional Amount	$ 100,000	100,000
Fixed Interest Rate	2.867%
Estimated Fair Value	$ 1,264	3,507
Interest Rate Swap Designated December 15, 2020 Tranche 1
Derivative [Line Items]
Notional Amount	$ 575,000	575,000
Fixed Interest Rate	1.415%
Estimated Fair Value	$ 25,507	34,537
Interest Rate Swap Designated December 15, 2020 Tranche 2
Derivative [Line Items]
Notional Amount	$ 125,000	125,000
Fixed Interest Rate	1.404%
Estimated Fair Value	$ 5,566	7,848
Interest Rate Swap Designated March 31, 2023
Derivative [Line Items]
Notional Amount	0	0
Estimated Fair Value	$ (1,864)	$ (1,829)

DERIVATIVE INSTRUMENTS - Schedule of Net Investment Hedges Derivatives (Details) € in Thousands, SFr in Thousands, $ in Thousands	Sep. 30, 2025 USD ($)	Sep. 30, 2025 CHF (SFr)	Sep. 30, 2025 EUR (€)	Feb. 28, 2025 USD ($)	Feb. 28, 2025 CHF (SFr)	Dec. 31, 2024 USD ($)	Dec. 31, 2024 CHF (SFr)	Dec. 31, 2024 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 CHF (SFr)
Cross-currency swap
Derivative [Line Items]
Aggregate Notional Amount				$ 368,400	SFr 328,100				$ 471,600	SFr 420,100
Designated as Hedging Instrument \| Net Investment Hedges \| Cross-currency swap
Derivative [Line Items]
Fair Value Asset (Liability)	$ (94,174)					$ (31,113)
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap One
Derivative [Line Items]
Fair Value Asset (Liability)	$ 0					4,827
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap One \| Long
Derivative [Line Items]
Fixed Rate	0.00%	0.00%	0.00%
Aggregate Notional Amount \| €			€ 38,820					€ 38,820
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap One \| Short
Derivative [Line Items]
Fixed Rate	2.19%	2.19%	2.19%
Aggregate Notional Amount	$ 45,000					45,000
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Two
Derivative [Line Items]
Fair Value Asset (Liability)	$ (58,351)					(27,951)
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Two \| Long
Derivative [Line Items]
Fixed Rate	0.00%	0.00%	0.00%
Aggregate Notional Amount \| SFr		SFr 240,175					SFr 240,175
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Two \| Short
Derivative [Line Items]
Fixed Rate	1.94%	1.94%	1.94%
Aggregate Notional Amount	$ 250,000					250,000
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Three
Derivative [Line Items]
Fair Value Asset (Liability)	$ (10,982)					(3,248)
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Three \| Long
Derivative [Line Items]
Fixed Rate	0.00%	0.00%	0.00%
Aggregate Notional Amount \| SFr		SFr 66,525					66,525
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Three \| Short
Derivative [Line Items]
Fixed Rate	2.54%	2.54%	2.54%
Aggregate Notional Amount	$ 75,000					75,000
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Four
Derivative [Line Items]
Fair Value Asset (Liability)	$ (12,761)					(4,741)
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Four \| Long
Derivative [Line Items]
Fixed Rate	0.00%	0.00%	0.00%
Aggregate Notional Amount \| SFr		SFr 68,483					68,483
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Four \| Short
Derivative [Line Items]
Fixed Rate	2.74%	2.74%	2.74%
Aggregate Notional Amount	$ 75,000					75,000
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Five
Derivative [Line Items]
Fair Value Asset (Liability)	$ (9,602)					0
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Five \| Long
Derivative [Line Items]
Fixed Rate	0.00%	0.00%	0.00%
Aggregate Notional Amount \| SFr		SFr 67,800					0
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Five \| Short
Derivative [Line Items]
Fixed Rate	3.24%	3.24%	3.24%
Aggregate Notional Amount	$ 75,000					0
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Six
Derivative [Line Items]
Fair Value Asset (Liability)	$ (2,478)					0
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Six \| Long
Derivative [Line Items]
Fixed Rate	0.00%	0.00%	0.00%
Aggregate Notional Amount \| SFr		SFr 59,693					SFr 0
Designated as Hedging Instrument \| Net Investment Hedges \| Cross Currency Interest Rate Swap Six \| Short
Derivative [Line Items]
Fixed Rate	2.66%	2.66%	2.66%
Aggregate Notional Amount	$ 75,000					$ 0

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
OPERATING ACTIVITIES:
Net loss	$ (514,770)	$ (26,379)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	113,402	103,304
Non-cash impairment charges	511,365	12,173
Deferred income tax benefit	(55,316)	(13,743)
Share-based compensation	12,745	17,225
Amortization of debt issuance costs and expenses associated with debt refinancing	4,590	4,193
Non-cash lease expense	(906)	(129)
Loss on disposal of property and equipment	490	1,337
Change in fair value of contingent consideration and others	(14,644)	(319)
Changes in assets and liabilities:
Accounts receivable	15,967	38,861
Inventories	(43,419)	(27,579)
Prepaid expenses and other current assets	(4,994)	(34,401)
Other non-current assets	3,335	(1,745)
Accounts payable, accrued expenses and other current liabilities	3,704	2,686
Contract liabilities	2,715	1,822
Other non-current liabilities	4,304	1,336
Net cash provided by operating activities	38,568	78,642
INVESTING ACTIVITIES:
Purchases of property and equipment	(64,222)	(74,818)
Cash paid for business acquisitions, net of cash acquired	0	(281,994)
Purchases of short-term investments	(8,502)	(48,997)
Proceeds from maturities of short-term investments	0	19,250
Net payments from swaps designated as net investment hedges	(432)	0
Net cash used in investing activities	(73,156)	(386,559)
FINANCING ACTIVITIES:
Proceeds from borrowings of long-term indebtedness	671,000	451,100
Payments on debt	(69,819)	(147,188)
Repayments of convertible debt	(574,983)	0
Payment of debt issuance costs	(3,930)	0
Purchases of treasury stock	(221)	(50,000)
Payments for contingent considerations	(16,451)	(11,923)
Proceeds from exercised stock options	957	6,398
Cash taxes paid in net equity settlement	(2,560)	(3,374)
Net cash provided by financing activities	3,993	245,013
Effect of exchange rate changes on cash and cash equivalents	16,406	1,659
Net decrease in cash and cash equivalents	(14,189)	(61,245)
Cash and cash equivalents at beginning of period	246,375	276,402
Cash and cash equivalents at end of period	$ 232,186	$ 215,157

REVENUES FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Dec. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Number of days from shipment to issue a credit on returned goods	90 days
Short-term portion of contract liability	$ 11,326	$ 10,483
Long-term portion of contract liability	$ 11,000
Product warranty period (up to)	2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected performance obligation, percentage	51.00%
Performance obligations expected to be satisfied, expected timing	12 months

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings
Balance, beginning of period, (in shares) at Dec. 31, 2023		90,920
Balance, beginning of period at Dec. 31, 2023	$ 1,587,884	$ 909	$ (647,262)	$ 1,302,484	$ (15,106)	$ 946,859
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2023			(12,751)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(3,281)					(3,281)
Other comprehensive income (loss), net of tax	4,460				4,460
Issuance of common stock through employee stock purchase plan (in shares)		23
Issuance of common stock through employee stock purchase plan	965			965
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)		541	16
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures	2,312	$ 2	$ 840	1,470
Share-based compensation		$ 4
Share-based compensation	5,612			5,608
Balance, end of period (in shares) at Mar. 31, 2024		91,484
Balance, end of period at Mar. 31, 2024	1,597,952	$ 915	$ (646,422)	1,310,527	(10,646)	943,578
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2024			(12,735)
Balance, beginning of period, (in shares) at Dec. 31, 2023		90,920
Balance, beginning of period at Dec. 31, 2023	1,587,884	$ 909	$ (647,262)	1,302,484	(15,106)	946,859
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2023			(12,751)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(26,379)
Balance, end of period (in shares) at Sep. 30, 2024		91,588
Balance, end of period at Sep. 30, 2024	1,521,587	$ 916	$ (691,810)	1,316,854	(24,854)	920,481
Balance, beginning of period, treasury stock (in shares) at Sep. 30, 2024			(14,454)
Balance, beginning of period, (in shares) at Mar. 31, 2024		91,484
Balance, beginning of period at Mar. 31, 2024	1,597,952	$ 915	$ (646,422)	1,310,527	(10,646)	943,578
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2024			(12,735)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(12,402)					(12,402)
Other comprehensive income (loss), net of tax	(8,080)				(8,080)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)		107
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures	(80)	$ 1	$ 20	(101)
Share-based compensation	7,305			7,305
Accelerated shares repurchased (in shares)			(1,273)
Accelerated shares repurchased	(50,500)		$ (34,351)	(16,149)
Balance, end of period (in shares) at Jun. 30, 2024		91,591
Balance, end of period at Jun. 30, 2024	1,534,195	$ 916	$ (680,753)	1,301,582	(18,726)	931,176
Balance, beginning of period, treasury stock (in shares) at Jun. 30, 2024			(14,008)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(10,695)					(10,695)
Other comprehensive income (loss), net of tax	(6,128)				(6,128)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)		(3)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures	(171)		$ 10	(181)
Share-based compensation	4,386			4,386
Accelerated shares repurchased (in shares)			(446)
Accelerated shares repurchased	0		$ (11,067)	11,067
Balance, end of period (in shares) at Sep. 30, 2024		91,588
Balance, end of period at Sep. 30, 2024	1,521,587	$ 916	$ (691,810)	1,316,854	(24,854)	920,481
Balance, beginning of period, treasury stock (in shares) at Sep. 30, 2024			(14,454)
Balance, beginning of period, (in shares) at Dec. 31, 2024		91,609
Balance, beginning of period at Dec. 31, 2024	$ 1,545,280	$ 916	$ (691,411)	1,323,431	(27,571)	939,915
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2024	(14,445)		(14,445)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (25,293)					(25,293)
Other comprehensive income (loss), net of tax	3,465				3,465
Issuance of common stock through employee stock purchase plan (in shares)		44
Issuance of common stock through employee stock purchase plan	957			957
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)		483	21
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures	(2,130)	$ 5	$ 1,032	(3,167)
Share-based compensation	1,860			1,860
Balance, end of period (in shares) at Mar. 31, 2025		92,136
Balance, end of period at Mar. 31, 2025	1,524,139	$ 921	$ (690,379)	1,323,081	(24,106)	914,622
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2025			(14,424)
Balance, beginning of period, (in shares) at Dec. 31, 2024		91,609
Balance, beginning of period at Dec. 31, 2024	$ 1,545,280	$ 916	$ (691,411)	1,323,431	(27,571)	939,915
Balance, beginning of period, treasury stock (in shares) at Dec. 31, 2024	(14,445)		(14,445)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (514,770)
Other comprehensive income (loss), net of tax	(4,404)
Balance, end of period (in shares) at Sep. 30, 2025		92,251
Balance, end of period at Sep. 30, 2025	$ 1,037,574	$ 923	$ (690,025)	1,333,506	(31,975)	425,145
Balance, beginning of period, treasury stock (in shares) at Sep. 30, 2025	(14,416)		(14,416)
Balance, beginning of period, (in shares) at Mar. 31, 2025		92,136
Balance, beginning of period at Mar. 31, 2025	$ 1,524,139	$ 921	$ (690,379)	1,323,081	(24,106)	914,622
Balance, beginning of period, treasury stock (in shares) at Mar. 31, 2025			(14,424)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(484,073)					(484,073)
Other comprehensive income (loss), net of tax	(6,801)				(6,801)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)		201	8
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures	(224)	$ 2	$ 345	(571)
Share-based compensation	5,341			5,341
Other Adjustments	279			279
Balance, end of period (in shares) at Jun. 30, 2025		92,337
Balance, end of period at Jun. 30, 2025	1,038,661	$ 923	$ (690,034)	1,328,130	(30,907)	430,549
Balance, beginning of period, treasury stock (in shares) at Jun. 30, 2025			(14,416)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(5,404)					(5,404)
Other comprehensive income (loss), net of tax	(1,068)				(1,068)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures (in shares)		(86)
Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures	(198)		$ 9	(207)
Share-based compensation	5,583			5,583
Balance, end of period (in shares) at Sep. 30, 2025		92,251
Balance, end of period at Sep. 30, 2025	$ 1,037,574	$ 923	$ (690,025)	$ 1,333,506	$ (31,975)	$ 425,145
Balance, beginning of period, treasury stock (in shares) at Sep. 30, 2025	(14,416)		(14,416)

FAIR VALUE MEASUREMENTS - Schedule Assets and Liabilities on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Assets:
Total assets	$ 300,794	$ 324,062
Liabilities:
Total liabilities	183,146	106,051
Level 1
Assets:
Cash and cash equivalents	232,186	246,375
Short-term investments	35,693	27,192
Level 2 \| Interest rate swaps
Assets:
Derivative asset	31,673	48,795
Level 2 \| Foreign currency forward contract
Assets:
Derivative asset	309	0
Liabilities:
Derivative liabilities	0	914
Level 2 \| Foreign currency forward contract \| Not Designated as Hedging Instrument
Assets:
Derivative asset	933	1,700
Level 2 \| Cross-currency swap \| Cash Flow Hedges
Liabilities:
Derivative liabilities	57,034	4,367
Level 2 \| Net Investment Hedges \| Net Investment Hedges
Liabilities:
Derivative liabilities	94,174	31,113
Level 3
Liabilities:
Contingent consideration	$ 31,938	$ 69,657

ACQUISITIONS AND DIVESTITURES (Tables)

9 Months Ended

Sep. 30, 2025

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

Schedule of Assets Acquired and Liabilities Assumed

The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:


Dollars in thousands	Estimated Fair Value		Estimated Useful Life
Current assets:
Cash	$	—
Trade accounts receivable, net of allowances of $3,885	23,716
Inventories, net	20,294
Prepaid expenses	273
Other current assets	476
Total current assets	$	44,759
Property, plant and equipment, net	7,716
Right of use asset - operating leases	989
Intangible assets, net
Completed technology	202,000		12 years
Trademarks/brand names	3,000		5 years
All other	17,000		4 years
Goodwill	62,482
Deferred tax assets	6,895
Total assets acquired	$	344,841

Current liabilities:
Accounts payable, trade	3,989
Contract liabilities	3,984
Accrued compensation	1,037
Accrued expenses and other current liabilities	2,278
Current portion of lease liability - operating leases	365
Total current liabilities	$	11,653
Lease liability - operating leases	624
Deferred tax liabilities	54,753
Total liabilities assumed	67,030

Net assets acquired	$	277,811

SEGMENT AND GEOGRAPHIC INFORMATION - Segment Reporting Information (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Segment Reporting Information [Line Items]
Total revenue, net	$ 402,062,000		$ 380,834,000	$ 1,200,320,000	$ 1,167,881,000
Cost of goods sold	195,071,000		180,596,000	589,565,000	534,892,000
Research and development	22,456,000		27,435,000	74,181,000	84,167,000
Selling, general & administrative	169,046,000		177,193,000	530,433,000	538,463,000
Intangible asset amortization	3,728,000		3,760,000	11,186,000	17,575,000
Goodwill impairment	0	$ 511,400,000	0	511,365,000	0	$ 0
Total costs and expenses	390,301,000		388,984,000	1,716,730,000	1,175,097,000
Operating income (loss)	11,761,000		(8,150,000)	(516,410,000)	(7,216,000)
Interest income	4,982,000		5,049,000	14,112,000	15,147,000
Interest expense	(22,725,000)		(19,373,000)	(62,582,000)	(51,648,000)
Other income, net	(842,000)		2,112,000	(2,932,000)	2,939,000
Loss before income taxes	(6,824,000)		(20,362,000)	(567,812,000)	(40,778,000)
Codman Specialty Surgical
Segment Reporting Information [Line Items]
Total revenue, net	292,583,000		270,782,000	877,204,000	828,977,000
Tissue Technologies
Segment Reporting Information [Line Items]
Total revenue, net	109,479,000		110,052,000	323,116,000	338,904,000
Operating Segments \| Codman Specialty Surgical
Segment Reporting Information [Line Items]
Total revenue, net	292,583,000		270,782,000	877,204,000	828,977,000
Cost of goods sold	93,289,000		95,829,000	288,070,000	281,443,000
Research and development	6,632,000		8,548,000	22,276,000	21,880,000
Selling, general & administrative	62,433,000		65,867,000	201,309,000	157,483,000
Intangible asset amortization	0		0	0	0
Goodwill impairment	0			388,106,000
Total costs and expenses	162,354,000		170,244,000	899,761,000	460,806,000
Operating income (loss)	130,229,000		100,538,000	(22,557,000)	368,171,000
Operating Segments \| Tissue Technologies
Segment Reporting Information [Line Items]
Total revenue, net	109,479,000		110,052,000	323,116,000	338,904,000
Cost of goods sold	42,668,000		40,529,000	138,499,000	119,512,000
Research and development	4,189,000		4,506,000	12,243,000	13,858,000
Selling, general & administrative	35,478,000		36,535,000	110,283,000	109,199,000
Intangible asset amortization	0		0	0	0
Goodwill impairment	0			123,259,000
Total costs and expenses	82,335,000		81,570,000	384,284,000	242,569,000
Operating income (loss)	27,144,000		28,482,000	(61,168,000)	96,335,000
Corporate and Other
Segment Reporting Information [Line Items]
Total revenue, net	0		0	0	0
Cost of goods sold	59,114,000		44,238,000	162,996,000	133,937,000
Research and development	11,635,000		14,381,000	39,662,000	48,429,000
Selling, general & administrative	71,135,000		74,791,000	218,841,000	271,781,000
Intangible asset amortization	3,728,000		3,760,000	11,186,000	17,575,000
Goodwill impairment	0			0
Total costs and expenses	145,612,000		137,170,000	432,685,000	471,722,000
Operating income (loss)	$ (145,612,000)		$ (137,170,000)	$ (432,685,000)	$ (471,722,000)

DEBT - Maximum Total Leverage Ratio Table (Details) - Senior Credit Facility	Jun. 06, 2025
June 30, 2025 through June 30, 2026
Debt Instrument [Line Items]
Debt instrument, covenant, maximum leverage ratio	5.00
September 30, 2026
Debt Instrument [Line Items]
Debt instrument, covenant, maximum leverage ratio	4.75
December 31, 2026
Debt Instrument [Line Items]
Debt instrument, covenant, maximum leverage ratio	4.50
March 31, 2027 and the last day of each fiscal quarter thereafter
Debt Instrument [Line Items]
Debt instrument, covenant, maximum leverage ratio	4.00

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

INVENTORIES

9 Months Ended

Sep. 30, 2025

Inventory Disclosure [Abstract]

INVENTORIES

Inventories, net consisted of the following:


Dollars in thousands	September 30, 2025		December 31, 2024
Finished goods	$	258,774	$	223,729
Work in process	100,010		79,423
Raw materials	130,322		125,938
Total inventories, net	$	489,106	$	429,090

BASIS OF PRESENTATION (Tables)

9 Months Ended

Sep. 30, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Restructuring and Related Costs

The following table summarizes the activity in the restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the nine months ended September 30, 2025 and 2024.


	Nine Months Ended September 30,
(Dollars in thousands)	2025		2024
Balance, beginning of the year	$	5,151	$	2,113
Charges:
Cost of Goods Sold	113		—
Research and development	417		—
Selling, general and administrative	6,780		—
Payments and other adjustments	(8,129)		(1,691)
Balance, end of the period	$	4,332	$	422

BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

General

The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.

In the opinion of management, the September 30, 2025 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K. The consolidated balance sheet as of December 31, 2024 was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three and nine-month period ended September 30, 2025 are not necessarily indicative of the results to be expected for the entire year.

The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the unaudited condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.

Recent Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. The amendments should be applied on a prospective basis. Retrospective application to all prior periods presented in the financial statements is permitted. The Company will adopt ASU 2023-09 for the annual period ending on December 31, 2025 on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), and in January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (“ASU 2025-01”). ASU 2024-03 requires additional disclosure of the nature of expenses included in the income statement. The standard requires disclosures about specific types of expenses included in the expense captions presented in the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its disclosures.

In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”), which removes all references to software development project stages and requires entities to start capitalizing software costs when both of the following occur: (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. This ASU is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted as of the beginning of a fiscal year. The amendments may be applied prospectively, retrospectively, or via a modified prospective transition method. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations, or cash flows.

Cash and cash equivalents

The Company had cash and cash equivalents, primarily consisting of cash on-hand, as well as time deposits with original maturities of three months or less and money market funds, which are highly liquid and readily convertible to cash, totaling approximately $232.2 million and $246.4 million at September 30, 2025 and December 31, 2024, respectively.

Short-term investments

The Company had short-term investments, primarily consisting of time deposits with original maturities between three months and one year, totaling approximately $35.7 million and $27.2 million at September 30, 2025 and December 31, 2024, respectively. The short-term investments are valued based on Level 1 measurements in the fair value hierarchy.

Employee termination benefits

The Company does not have a written severance plan but has a history of providing benefits for employees in the case of involuntary termination. In situations outside the U.S., there are minimum statutory termination benefits requirements by country that must be paid to the affected employees. The Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In situations where the Company pays out termination benefits in excess of statutory minimum amounts based on management’s discretion, the Company records these termination costs once communication is made to the affected employees.

The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met.

The Company incurred employee termination costs on restructuring activities in the consolidated statement of operations for the nine months ended September 30, 2025 and 2024. The following table summarizes the activity in the restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the nine months ended September 30, 2025 and 2024.


	Nine Months Ended September 30,
(Dollars in thousands)	2025		2024
Balance, beginning of the year	$	5,151	$	2,113
Charges:
Cost of Goods Sold	113		—
Research and development	417		—
Selling, general and administrative	6,780		—
Payments and other adjustments	(8,129)		(1,691)
Balance, end of the period	$	4,332	$	422

INCOME TAXES

9 Months Ended

Sep. 30, 2025

Income Tax Disclosure [Abstract]

INCOME TAXES

The following table provides a summary of the Company’s effective tax rate:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Reported tax rate	20.8	%	47.5	%	9.3	%	35.3	%

The Company’s effective income tax rates for the three months ended September 30, 2025 and 2024 were 20.8% and 47.5%, respectively. For the three months ended September 30, 2025, the Company’s effective tax rate was primarily driven by the tax expense generated in certain profitable foreign jurisdictions and the inclusion of Global Intangible Low Taxed Income (“GILTI”); offset by federal, state, and international tax benefits generated from operating losses and favorable prior year tax return positions. For the three months ended September 30, 2024, the tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income.

The Company’s effective income tax rates for the nine months ended September 30, 2025 and 2024 were 9.3% and 35.3%, respectively. For the nine months ended September 30, 2025, the Company’s effective tax rate was primarily driven by the goodwill impairment charge, as a portion of the charge is non-deductible for tax, as well as the inclusion of GILTI and the global minimum tax in certain foreign jurisdictions; offset by federal, state, and international tax benefits generated from operating losses and favorable prior year tax return positions. For the nine months ended September 30, 2024, the tax rate is primarily due to the limitation of foreign tax credits in the U.S. and the limitation of federal tax credits in Switzerland, caused by lower book income and a $1.9 million shortfall from stock-based compensation.

Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes a number of significant provisions, including the permanent extension of certain expiring provisions of the 2017 Tax Cuts and Jobs Act. Additionally, the OBBBA contains changes to the capitalization of research and development expenses, accelerated fixed asset depreciation, and limitations on deductions for interest expense, among other provisions. The Company has evaluated the impact of the OBBBA on its financial statements and estimates the financial impact for the year ended December 31, 2025 to be approximately $4.4 million.

Further, legislation in foreign jurisdictions may be enacted, in continued response to the ongoing base erosion and profit-sharing (“BEPS”) project led by the Organization for Economic Cooperation and Development (“OECD”). The OECD released model rules related to a new 15% global minimum tax regime (“Pillar 2”). A number of the jurisdictions that the Company operates in have adopted some form of the model rules, which became effective beginning in 2024. The Pillar 2 rules are complex and provide for delays for implementing the tax during the early transition years, if certain conditions are met. The Company is calculating an immaterial expense related to Pillar 2 tax liability for the year ending December 31, 2025. Related changes in U.S. and non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate. The Company will continue to monitor legislative activity across its U.S. and non-U.S. jurisdictions.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

ACQUISITIONS AND DIVESTITURES - Business Combination, Schedule of Purchase Price Allocation (Details) - USD ($) $ in Thousands	Apr. 01, 2024	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Trade accounts receivable, allowance		$ 5,637	$ 6,917
Goodwill		$ 615,199	$ 1,096,952
Acclarent Inc.
Current assets:
Cash	$ 0
Trade accounts receivable, allowance	3,885
Trade accounts receivable, net of allowances of $3,885	23,716
Inventories, net	20,294
Prepaid expenses	273
Other current assets	476
Total current assets	44,759
Property, plant and equipment, net	7,716
Right of use asset - operating leases	$ 989
Estimated Useful Life	11 years
Goodwill	$ 62,482
Deferred tax assets	6,895
Total assets acquired	344,841
Current liabilities:
Accounts payable, trade	3,989
Contract liabilities	3,984
Accrued compensation	1,037
Accrued expenses and other current liabilities	2,278
Current portion of lease liability - operating leases	365
Total current liabilities	11,653
Lease liability - operating leases	624
Deferred tax liabilities	54,753
Total liabilities assumed	67,030
Net assets acquired	277,811
Acclarent Inc. \| Completed technology
Current assets:
Intangible assets, net	$ 202,000
Estimated Useful Life	12 years
Acclarent Inc. \| Trademarks/brand names
Current assets:
Intangible assets, net	$ 3,000
Estimated Useful Life	5 years
Acclarent Inc. \| All other
Current assets:
Intangible assets, net	$ 17,000
Estimated Useful Life	4 years

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

9 Months Ended

Sep. 30, 2025

Equity [Abstract]

Schedule of Comprehensive Income (Loss)

Comprehensive loss for the three and nine months ended September 30, 2025 and 2024:


	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in thousands	2025		2024		2025		2024
Net loss	$	(5,404)	$	(10,695)	$	(514,770)	$	(26,379)
Foreign currency translation adjustment	(1,701)		5,386		6,484		(2,558)
Change in unrealized (gain) loss on derivatives, net of tax	800		(11,044)		(10,405)		(6,714)
Pension liability adjustment, net of tax	(167)		(470)		(483)		(475)
Comprehensive loss, net	$	(6,472)	$	(16,823)	$	(519,174)	$	(36,126)

Schedule of Changes in Accumulated Other Comprehensive Loss by Component

Changes in accumulated other comprehensive loss by component between December 31, 2024 and September 30, 2025 are presented in the table below, net of tax:


Dollars in thousands	Gains and Losses on Derivatives		Defined Benefit Pension Items		Foreign Currency Items		Total
Balance at January 1, 2025	$	26,612	$	4,028	$	(58,211)	$	(27,571)
Other comprehensive (loss) gain	(41,147)				13,510		(27,637)
Less: Amounts reclassified from accumulated other comprehensive income, net	(30,742)		483		7,026		(23,233)
Net current-period other comprehensive (loss) gain	(10,405)		(483)		6,484		(4,404)
Balance at September 30, 2025	$	16,207	$	3,545	$	(51,727)	$	(31,975)

DERIVATIVE INSTRUMENTS - Schedule of Cross Currency Swap Derivatives (Details) SFr in Thousands, $ in Thousands	Sep. 30, 2025 USD ($)	Sep. 30, 2025 CHF (SFr)	Feb. 28, 2025 USD ($)	Feb. 28, 2025 CHF (SFr)	Dec. 31, 2024 USD ($)	Dec. 31, 2024 CHF (SFr)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 CHF (SFr)
Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	$ 900,000				$ 1,125,000
Fair Value Asset (Liability)	31,673				48,795
Cross Currency Interest Rate Swap One \| Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Fair Value Asset (Liability)	$ 0
Cross Currency Interest Rate Swap One \| Cash Flow Hedges \| Designated as Hedging Instrument \| Long
Derivative [Line Items]
Fixed Interest Rate	3.00%	3.00%
Aggregate Notional Amount \| SFr		SFr 0				SFr 328,136
Fair Value Asset (Liability)					(4,367)
Cross Currency Interest Rate Swap One \| Cash Flow Hedges \| Designated as Hedging Instrument \| Short
Derivative [Line Items]
Fixed Interest Rate	3.98%	3.98%
Aggregate Notional Amount	$ 0				368,362
Cross Currency Interest Rate Swap Two \| Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Fair Value Asset (Liability)	$ (57,034)
Cross Currency Interest Rate Swap Two \| Cash Flow Hedges \| Designated as Hedging Instrument \| Long
Derivative [Line Items]
Fixed Interest Rate	3.25%	3.25%
Aggregate Notional Amount \| SFr		SFr 310,887				SFr 0
Fair Value Asset (Liability)					0
Cross Currency Interest Rate Swap Two \| Cash Flow Hedges \| Designated as Hedging Instrument \| Short
Derivative [Line Items]
Fixed Interest Rate	6.14%	6.14%
Aggregate Notional Amount	$ 348,997				0
Cross-currency swap
Derivative [Line Items]
Aggregate Notional Amount			$ 368,400	SFr 328,100			$ 471,600	SFr 420,100
Cross-currency swap \| Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Fair Value Asset (Liability)	$ (57,034)				$ (4,367)

DERIVATIVE INSTRUMENTS (Tables)

9 Months Ended

Sep. 30, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments

The Company held the following interest rate swaps as of September 30, 2025 and December 31, 2024 (dollar amounts in thousands):


	September 30, 2025		December 31, 2024							September 30, 2025		December 31, 2024
Hedged Item	Notional Amount				Designation Date	Effective Date	Termination Date	Fixed Interest Rate		Estimated Fair Value
										Asset (Liability)


1-month Term SOFR Loan	—		75,000		October 10, 2018	July 1, 2020	June 30, 2025	3.220	%	—		421
1-month Term SOFR Loan	—		75,000		October 10, 2018	July 1, 2020	June 30, 2025	3.199	%	—		502
1-month Term SOFR Loan	—		75,000		October 10, 2018	July 1, 2020	June 30, 2025	3.209	%	—		403
1-month Term SOFR Loan	100,000		100,000		December 18, 2018	December 30, 2022	December 31, 2027	2.885	%	1,200		3,406
1-month Term SOFR Loan	100,000		100,000		December 18, 2018	December 30, 2022	December 31, 2027	2.867	%	1,264		3,507
1-month Term SOFR Loan	575,000		575,000		December 15, 2020	July 31, 2025	December 31, 2027	1.415	%	25,507		34,537
1-month Term SOFR Loan	125,000		125,000		December 15, 2020	July 1, 2025	December 31, 2027	1.404	%	5,566		7,848
Basis Swap (1)	—		—		March 31, 2023	March 24, 2023	December 31, 2027	N/A		(1,864)		(1,829)
	$	900,000	$	1,125,000						$	31,673	$	48,795
(1) The notional of the basis swap amortizes to match the total notional of the interest rate swap portfolio over time

The Company held the following cross-currency rate swaps as of September 30, 2025 and December 31, 2024 (dollar amounts in thousands):


					September 30, 2025	December 31, 2024	September 30, 2025		December 31, 2024
	Effective Date	Termination Date	Fixed Rate	Aggregate Notional Amount			Fair Value Asset (Liability)

Pay CHF	December 21, 2020	February 19, 2025	3.00%	CHF	—	328,136	—		(4,367)
Receive U.S.$			3.98%	$	—	368,362

Pay CHF	February 20, 2025	December 20, 2030	3.25%	CHF	310,887	—	(57,034)		—
Receive U.S.$			6.14%	$	348,997	—

Total							$	(57,034)	$	(4,367)

The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2025 and December 31, 2024, respectively (dollar amounts in thousands):


					September 30, 2025	December 31, 2024	September 30, 2025		December 31, 2024
	Effective Date	Termination Date	Fixed Rate	Aggregate Notional Amount			Fair Value Asset (Liability)

Pay EUR	October 3, 2018	September 30, 2025	—%	EUR	38,820	38,820	—		4,827
Receive U.S.$			2.19%	$	45,000	45,000

Pay CHF	May 26, 2022	December 16, 2028	—%	CHF	240,175	240,175	(58,351)		(27,951)
Receive U.S.$			1.94%	$	250,000	250,000

Pay CHF	November 17, 2023	December 17, 2029	—%	CHF	66,525	66,525	(10,982)		(3,248)
Receive U.S.$			2.54%	$	75,000	75,000

Pay CHF	May 6, 2024	December 18, 2030	—%	CHF	68,483	68,483	(12,761)		(4,741)
Receive U.S.$			2.74%	$	75,000	75,000

Pay CHF	February 21, 2025	December 15, 2031	—%	CHF	67,800	—	(9,602)		—
Receive U.S.$			3.24%	$	75,000	—

Pay CHF	July 25, 2025	December 15, 2032	—%	CHF	59,693	—	(2,478)		—
Receive U.S.$			2.66%	$	75,000	—

Total							$	(94,174)	$	(31,113)

Summary of Fair Value in Balance Sheet for Derivatives Designated as Hedging Instruments

The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024:


	Fair Value as of
Location on Balance Sheet (1):	September 30, 2025		December 31, 2024
Dollars in thousands
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Interest rate swap	$	17,999	$	12,320
Cross-currency swap	3,518		—
Foreign currency forward contracts	309		—
Net Investment Hedges
Cross-currency swap	7,484		8,605
Other assets
Cash Flow Hedges
Interest rate swap	15,538		38,302




Total derivatives designated as hedges — Assets	$	44,848	$	59,227

Derivatives designated as hedges — Liabilities:
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap	$	1,144	$	684
Cross-currency swap	—		4,367
Foreign currency forward contracts	—		914
Net Investment Hedges
Cross-currency swap	6,670		210
Other liabilities
Cash Flow Hedges
Interest rate swap	720		1,145
Cross-currency swap	60,552		—

Net Investment Hedges
Cross-currency swap	94,988		39,507
Total derivatives designated as hedges — Liabilities	$	164,074	$	46,827

(1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.

Effect of Derivative Instruments Designated as Cash Flow Hedges and Net Investment Hedges on Statements of Operations


Dollars in thousands	Balance in AOCI Beginning of Quarter		Amount of Gain (Loss) Recognized in AOCI		Amount of Gain (Loss) Reclassified from AOCI into Earnings		Balance in AOCI End of Quarter		Location in Statements of Operations
Three Months Ended September 30, 2025
Cash Flow Hedges
Interest rate swap	$	35,051	$	1,253	$	4,629	$	31,675	Interest expense
Cross-currency swap	(14,767)		9,033		5,046		(10,780)		Other income, net
Foreign Currency Forward Contract	1,906		(162)		—		1,744		Cost of sales
Net Investment Hedges
Cross-currency swap	(96,173)		4,955		3,407		(94,625)		Interest income
	$	(73,983)	$	15,079	$	13,082	$	(71,986)
Three Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap	$	53,116	$	(17,133)	$	4,135	$	31,848	Interest expense
Cross-currency swap	(16,867)		(16,625)		(22,089)		(11,403)		Other income, net
Foreign Currency Forward Contract	$	(430)	$	474	$	(119)	$	163
Net Investment Hedges
Cross-currency swap	(29,466)		(21,051)		2,739		(53,256)		Interest income
	$	6,353	$	(54,335)	$	(15,334)	$	(32,648)

Dollars in thousands	Balance in AOCI Beginning of Year		Amount of Gain (Loss) Recognized in AOCI		Amount of Gain (Loss) Reclassified from AOCI into Earnings		Balance in AOCI End of Quarter		Location in Statements of Operations
Nine Months Ended September 30, 2025
Cash Flow Hedges
Interest rate swap	$	48,794	$	(9,630)	$	7,489	$	31,675	Interest expense
Cross-currency swap	(11,621)		(40,504)		(41,345)		(10,780)		Other income (expense), net
Foreign currency forward contract	(624)		1,941		(427)		1,744		Cost of sales
Net Investment Hedges
Cross-currency swap	(31,130)		(54,356)		9,139		(94,625)		Interest income
	$	5,419	$	(102,549)	$	(25,144)	$	(71,986)
Nine Months Ended September 30, 2024
Cash Flow Hedges
Interest rate swap	$	43,556	$	2,678	$	14,386	$	31,848	Interest expense
Cross-currency swap	(15,763)		13,505		9,145		(11,403)		Other income (expense), net
Foreign currency forward contract	—		$	(159)	$	(322)	163
Net Investment Hedges
Cross-currency swap	(45,498)		(364)		7,394		(53,256)		Interest income
	$	(17,705)	$	15,660	$	30,603	$	(32,648)

Derivatives Not Designated as Hedging Instruments

The following table summarizes the gains and losses on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:


Dollars in thousands	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Foreign currency forward contracts	(170)		—		(1,865)		—
Foreign currency swaps	(57)		$	10	(39)		$	385
Total	$	(227)	$	10	$	(1,904)	$	385

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Goodwill [Roll Forward]
Goodwill at beginning of period				$ 1,096,952,000
Impairment	$ 0	$ (511,400,000)	$ 0	(511,365,000)	$ 0	$ 0
Foreign currency translation				29,612,000
Goodwill at end of period	615,199,000			615,199,000		1,096,952,000
Acclarent Inc.
Goodwill [Roll Forward]
Impairment				(511,365,000)
Codman Specialty Surgical
Goodwill [Roll Forward]
Goodwill at beginning of period				715,730,000
Foreign currency translation				16,567,000
Goodwill at end of period	344,191,000			344,191,000		715,730,000
Codman Specialty Surgical \| Acclarent Inc.
Goodwill [Roll Forward]
Impairment				(388,106,000)
Tissue Technologies
Goodwill [Roll Forward]
Goodwill at beginning of period				381,222,000
Foreign currency translation				13,045,000
Goodwill at end of period	$ 271,008,000			271,008,000		$ 381,222,000
Tissue Technologies \| Acclarent Inc.
Goodwill [Roll Forward]
Impairment				$ (123,259,000)

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

+ Details

- Definition

Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References + Details

LEASES AND RELATED PARTY LEASES

9 Months Ended

Sep. 30, 2025

Leases [Abstract]

LEASES AND RELATED PARTY LEASES

The Company leases administrative, manufacturing, research and distribution facilities, and vehicles through operating lease agreements. The Company has no finance leases as of September 30, 2025. Many of the Company’s leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components.

Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company’s sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the Right of Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.

As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.

Total operating lease expense for the nine months ended September 30, 2025 and September 30, 2024 was $17.8 million and $18.8 million, respectively, which includes $0.2 million in related party operating lease expense.

Supplemental balance sheet information related to operating leases were as follows:


Dollars in thousands, except lease term and discount rate	September 30, 2025			December 31, 2024
ROU assets	$	138,187		$	144,042

Current lease liabilities	13,826			14,540
Non-current lease liabilities	160,933			166,930
Total lease liabilities	$	174,759		$	181,470

Weighted average remaining lease term (in years):
Leased facilities	16.0 years			16.1 years
Leased vehicles	2.8 years			2.3 years

Weighted average discount rate:
Leased facilities	5.3		%	5.4		%
Leased vehicles	3.2		%	2.8		%

Supplemental cash flow information related to leases for the nine months ended September 30, 2025 and 2024 were as follows:


Dollars in thousands	September 30, 2025		September 30, 2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	17,729	$	18,255

ROU assets obtained in exchange for lease liabilities, net of modifications:
Operating leases	$	6,493	$	1,575

Future minimum lease payments under operating leases at September 30, 2025 were as follows:


Dollars in thousands	Related Parties		Third Parties		Total
Remainder of 2025	$	74	$	5,698	$	5,772
2026	296		17,324		17,620
2027	296		20,620		20,916
2028	296		18,187		18,483
2029	246		17,869		18,115
2030	—		17,642		17,642
Thereafter	—		163,525		163,525
Total minimum lease payments	$	1,208	$	260,865	$	262,073
Less: Imputed interest					87,314
Total lease liabilities					174,759
Less: Current lease liabilities					13,826
Long-term lease liabilities					160,933

There were no future minimum lease payments under finance leases at September 30, 2025.

Related Party Leases

The Company leases one of its manufacturing facilities in Plainsboro, New Jersey, from a general partnership that is 50% owned by a principal stockholder of the Company. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.

GOODWILL AND OTHER INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2025 were as follows:


Dollars in thousands	Codman Specialty Surgical		Tissue Technologies		Total
Goodwill at December 31, 2024	$	715,730	$	381,222	$	1,096,952
Impairment	(388,106)		(123,259)		(511,365)
Foreign currency translation	16,567		13,045		29,612
Goodwill at September 30, 2025	$	344,191	$	271,008	$	615,199

In accordance with FASB Topic 350, Intangibles—Goodwill and Other (“ASC 350”), goodwill is not subject to amortization but is tested for impairment at the reporting unit level annually in the third quarter. Additionally, the Company may perform interim tests of goodwill for impairment if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. An impairment loss is recognized when the reporting unit’s carrying amount exceeds its estimated fair value.

The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test. The quantitative test uses a combination of both an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilizes the estimated discounted cash flows for the reporting unit, while the market approach utilizes comparable publicly-traded companies’ revenue and earnings

before interest, taxes, depreciation, and amortization (“EBITDA”) multiples. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, cost of sales, terminal growth rates, and a discount rate for each reporting unit. Discount rates are determined using a weighted average cost of capital for risk factors specific to each reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and slight changes in these assumptions could have a significant impact on the concluded value. The estimates and assumptions applied represent a Level 3 measurement in the fair value hierarchy. Level 3 inputs are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.

During the second quarter of 2025, the Company performed a quantitative assessment of its Tissue Technologies, Neurosurgery, and Instruments and ENT reporting units in accordance with ASC 350 due to the decrease in the price per share of the Company’s common stock related to a number of factors including recent tariff changes that have created broad economic uncertainty and the impact of quality, operational, and supply issues. The Company recognized an aggregate charge of $511.4 million in goodwill impairment expense in the consolidated statement of operations in the second quarter of 2025. The quantitative test for the Tissue Technologies reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 13.5% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Technologies reporting unit was less than its carrying amount and recognized an impairment of $123.3 million. The quantitative test for the Neurosurgery reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 13.5% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Neurosurgery reporting unit was less than its carrying amount and recognized an impairment of $249.0 million. The quantitative test for the Instruments and ENT reporting unit utilized a terminal growth rate of 2.5% and a discount rate of 12.0% in the income approach. The Company determined, after performing the quantitative analysis, that the fair value of the Instruments and ENT reporting unit was less than its carrying amount and recognized an impairment of $139.1 million.

In the third quarter of 2025, the Company performed its annual test of its reporting units for impairment and completed a qualitative evaluation of its Tissue Technologies and Neurosurgery reporting units. The Instruments and ENT reporting unit had been deemed fully-impaired during the second quarter of 2025 and was excluded from this evaluation. After performing the qualitative analysis, the Company concluded that it was more likely than not that the fair values of the Tissue Technologies and Neurosurgery reporting units were greater than their carrying amounts. Therefore, it was not necessary to perform a quantitative impairment test.

The Company did not recognize any goodwill impairment charges during 2024.

Other Intangible Assets

The components of the Company’s identifiable intangible assets were as follows:


	September 30, 2025
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	17 years	$	1,484,605	$	(608,295)	$	876,310
Customer relationships	12 years	169,246		(143,789)		25,457
Trademarks/brand names	27 years	103,340		(46,639)		56,701
Codman tradename	Indefinite	179,516		—		179,516
Supplier relationships	30 years	30,211		(19,860)		10,351
All other	6 years	23,428		(11,618)		11,810
		$	1,990,346	$	(830,201)	$	1,160,145


	December 31, 2024
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	17 years	$	1,452,545	$	(525,959)	$	926,586
Customer relationships	12 years	166,038		(137,186)		28,852
Trademarks/brand names	27 years	99,951		(42,173)		57,778
Codman tradename	Indefinite	168,202		—		168,202
Supplier relationships	30 years	30,211		(19,126)		11,085
All other	6 years	22,820		(7,735)		15,085
		$	1,939,767	$	(732,179)	$	1,207,588

Intangible Assets with Indefinite Lives

The Company does not amortize intangible assets with indefinite lives but tests its intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC 350. Additionally, the Company performs interim tests of its intangible assets with indefinite lives for impairment if an event occurs or circumstances change that could potentially reduce the fair value of an indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.

During the second quarter of 2025 the Company performed a quantitative assessment of its Codman tradename intangible asset in accordance with ASC 350 due to the decrease in the price per share of the Company’s common stock related to a number of factors including recent tariff changes that have created broad economic uncertainty and the impact of quality, operational, and supply issues. In performing this test, the Company utilized a discount rate of 14.5%. The assumptions used in evaluating the Codman tradename for impairment are subject to change and are tracked against historical results by management. Based on the results of the quantitative test, the Company recorded no impairment to the Codman tradename intangible asset.

In the third quarter of 2025, the Company performed its annual test of its intangible assets with indefinite lives for impairment and completed a qualitative evaluation of its Codman tradename intangible asset. After performing the qualitative analysis, the Company concluded that it was more likely than not that the fair value of the Codman tradename intangible asset was greater than its carrying amount. Therefore, it was not necessary to perform a quantitative impairment test.

The Company did not recognize any impairment charges on its intangible assets with indefinite lives during 2024.

Intangible Assets with Definite Lives

Developed technologies and other definite-lived intangible assets are amortized over their estimated useful lives either using the straight-line method or, if reliably determinable, based on the pattern of which the economic benefit of the asset is expected to be utilized. Definite-lived intangible assets are periodically evaluated for impairment in accordance with FASB Topic 360, Property, Plant and Equipment (“ASC 360”) whenever events or changes in circumstances indicate that a definite-lived intangible asset’s carrying value may not be recoverable.

Total amortization of intangible assets for the three and nine months ended September 30, 2025 was $26.9 million and $80.1 million, respectively. Of this amount, $23.1 million and $69.0 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold.

Total amortization of intangible assets for the three and nine months ended September 30, 2024 was $25.6 million and $78.7 million, respectively. Of this amount, $21.8 million and $61.1 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold. $7.1 million related to the impairment of a customer relationship intangible and the remainder were included in intangible amortization in the statement of operations.

Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $26.9 million for the remainder of 2025, $107.6 million in 2026, $106.5 million in 2027, $103.0 million in 2028, $97.7 million in 2029, $91.6 million in 2030 and $447.6 million thereafter.

In the first quarter of 2024, due to third-party audit findings and an update to the estimated timeframe to resume the commercial distribution of products manufactured in the Company's manufacturing facility located in Boston, Massachusetts (the “Boston facility”), the Company elected to perform quantitative impairment testing on certain definite-lived intangible assets including completed technology and customer relationships in accordance with ASC 360. The Company recorded an impairment charge related to the definite-lived intangible asset associated with the customer relationships of $7.1 million in intangible asset amortization in the consolidated statement of operations. With respect to the definite-lived intangible assets associated with the completed technology of SurgiMend® and PriMatrix®, the Company determined that the carrying amount of these definite-lived intangible assets were recoverable and, therefore, the intangible assets were not deemed to be impaired. In the second quarter of 2024, the Company approved a plan to transition the commercial distribution of SurgiMend and PriMatrix from the Boston facility to the Company’s manufacturing facility in Braintree, Massachusetts (the “Braintree facility”). The Company considered the impact to the update to the estimated timeframe to resume the commercial distribution of products manufactured in the Boston facility on the assumptions used in the quantitative assessment of the definite-lived intangible assets completed in the first quarter of 2024, which did not require further evaluation for impairment. The carrying values of SurgiMend and PriMatrix are $27.4 million and $21.1 million, respectively, as of September 30, 2025.

Potential Impact of Risks and Uncertainties on Management’s Estimates

The rapidly evolving tariff changes imposed by the U.S. and other countries since early 2025 have created increased risks and uncertainties surrounding the Company’s future results of operations. In 2025 President Trump has announced reciprocal tariffs on many countries and certain countries, such as China, have responded with retaliatory tariffs. In September 2025, the U.S. Department of Commerce initiated national security investigations into medical equipment, devices, and robotics. The tariff environment has continued to shift throughout the 2025 calendar year, with new measures being proposed, paused, implemented, and countered, contributing to broader trade policy uncertainty. The assumptions used by the Company in its quantitative tests of goodwill and intangible assets are inherently subject to uncertainty and slight changes in these assumptions, including the extent and duration of any subsequent changes in U.S. import tariffs and reciprocal measures by China and the resulting impact on general economic conditions and on the Company’s business, could have a significant impact on the concluded values.

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2025

Fair Value Disclosures [Abstract]

Schedule of Fair Value Measurements, Recurring and Nonrecurring

Assets and liabilities measured and recorded at fair value on a recurring basis as of September 30, 2025 and December 31, 2024 consisted of the following:


Dollars in thousands	Fair Value Measurement	September 30, 2025		December 31, 2024
Assets:
Cash and cash equivalents	Level 1	$	232,186	$	246,375
Short-term investments	Level 1	35,693		27,192
Interest rate swaps	Level 2	31,673		48,795

Foreign currency forward contracts	Level 2	309		—
Foreign currency forward contracts (not designated as hedges)	Level 2	933		1,700
Total Assets:		$	300,794	$	324,062

Liabilities:
Cross currency rate swaps	Level 2	$	57,034	$	4,367
Net investment hedges	Level 2	94,174		31,113
Foreign currency forward contracts	Level 2	—		914
Contingent consideration	Level 3	31,938		69,657

Total Liabilities:		$	183,146	$	106,051

LEASES AND RELATED PARTY LEASES (Tables)

9 Months Ended

Sep. 30, 2025

Leases [Abstract]

Supplemental Balance Sheet Information

Supplemental balance sheet information related to operating leases were as follows:


Dollars in thousands, except lease term and discount rate	September 30, 2025			December 31, 2024
ROU assets	$	138,187		$	144,042

Current lease liabilities	13,826			14,540
Non-current lease liabilities	160,933			166,930
Total lease liabilities	$	174,759		$	181,470

Weighted average remaining lease term (in years):
Leased facilities	16.0 years			16.1 years
Leased vehicles	2.8 years			2.3 years

Weighted average discount rate:
Leased facilities	5.3		%	5.4		%
Leased vehicles	3.2		%	2.8		%

Supplemental Cash Flow Information

Supplemental cash flow information related to leases for the nine months ended September 30, 2025 and 2024 were as follows:


Dollars in thousands	September 30, 2025		September 30, 2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	17,729	$	18,255

ROU assets obtained in exchange for lease liabilities, net of modifications:
Operating leases	$	6,493	$	1,575

Schedule of Operating Lease Maturities

Future minimum lease payments under operating leases at September 30, 2025 were as follows:


Dollars in thousands	Related Parties		Third Parties		Total
Remainder of 2025	$	74	$	5,698	$	5,772
2026	296		17,324		17,620
2027	296		20,620		20,916
2028	296		18,187		18,483
2029	246		17,869		18,115
2030	—		17,642		17,642
Thereafter	—		163,525		163,525
Total minimum lease payments	$	1,208	$	260,865	$	262,073
Less: Imputed interest					87,314
Total lease liabilities					174,759
Less: Current lease liabilities					13,826
Long-term lease liabilities					160,933

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2025

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.

In the ordinary course of its business, the Company is involved in, from time to time, various legal actions, including any matters described below, involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, some of which have been settled by the Company. In the opinion of management, such matters are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.

The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded and actual results may differ from these estimates. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.

On December 21, 2023, Fortis Advisors, LLC (representative of the security holders of ACell, Inc. (“ACell”)) filed for arbitration against Integra LifeSciences before the Court of International Arbitration of the International Chamber of Commerce claiming breach of contract related to the earnout consideration from the 2021 acquisition of ACell. Refer to the “Contingent Consideration” subheading of this Note for additional information on the ACell contingent consideration. The Company believes that it has strong defenses to the allegations in the arbitration and intends to defend the matter vigorously.

On September 12, 2023, a securities class action complaint, captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation, No. 23-cv-20321 (D.N.J.), was filed by a purported stockholder of the Company in the United States District Court for the District of New Jersey (the “Pembroke Litigation”) against the Company and certain of the Company’s current and former executive officers. The Pembroke Litigation, filed on behalf of a putative class of stockholders who purchased or acquired the Company’s common stock between March 11, 2019 and May 22, 2023, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, on the basis of purportedly materially false and misleading statements and omissions relating to certain quality systems issues identified by the FDA at the Company’s Boston facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The complaint seeks, among other things, compensatory damages, attorneys’ fees, expert fees, and other costs. The Company believes that it has strong defenses to the allegations in the Pembroke Litigation, and intends to continue to defend the matter vigorously. On July 1, 2025, the class action complaint was dismissed without prejudice. The plaintiffs filed a Second Amended Complaint on August 14, 2025. The Company has filed a motion to dismiss the Second Amended Complaint on October 14, 2025.

On February 21, 2025, a derivative lawsuit captioned Grabowsky v. Integra LifeSciences Holding Corp. et al, No. 3:25-cv-01399 (D.N.J.) was filed in the United States District Court for the District of New Jersey. The action purports to assert derivative claims on behalf of the Company against its current Board of Directors and certain of its current or former officers and directors. The action asserts claims that the individual defendants breached their fiduciary duties and harmed the Company by making false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration (“FDA”) at the Company’s Boston facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. On March 28, 2025, the derivative lawsuit was voluntarily dismissed by the plaintiff. On April 1, 2025 the lawsuit was dismissed with prejudice.

On May 13, 2025 and May 16, 2025, derivative lawsuits captioned Leverett v. Integra LifeSciences Holding Corp. et al, No. 3:2025-cv-04214 (D.N.J.) and Simpkins v. Integra LifeSciences Holding Corp. et al, No. 3:2025-cv-04446 (D.N.J.) were filed in the United States District Court for the District of New Jersey. The actions purport to assert derivative claims on behalf of the Company against its current Board of Directors and certain of its current or former officers and directors. The actions assert claims that the individual defendants breached their fiduciary duties and harmed the Company by making false and misleading statements and omissions relating to certain quality systems issues identified by the U.S. Food and Drug Administration (“FDA”) at the Company’s Boston, Massachusetts manufacturing facility, the Company’s efforts to remediate those issues, and the Company’s forecasts for certain products in its Tissue Technologies segment. The Company believes that it has strong defenses to the allegations in the lawsuits and intends to defend the matters vigorously.

Contingent Consideration

The Company determined the fair value of contingent consideration during the nine month period ended September 30, 2025 and September 30, 2024 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period.

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2025 and September 30, 2024 is as follows (in thousands):


Nine Months Ended September 30, 2025	Contingent Consideration Liability Related to Acquisition of:
	Arkis (1)		Derma Sciences (2)		ACell (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2025	$	12,968	$	2,686	$	3	54,000		69,657
Payment	(5,000)		—		—		(18,075)		(23,075)
Change in fair value of contingent consideration liabilities	(1,770)		(2,349)		—		(10,525)		(14,644)
Balance as of September 30, 2025	6,198		337		3		25,400		31,938

Short-Term - Accrued expenses and other liabilities	$	—	$	—	$	3	$	25,400	$	25,403
Long-Term - Other liabilities	6,198		337		—		—		6,535
Total	6,198		337		3		25,400		31,938


Nine Months Ended September 30, 2024	Contingent Consideration Liability Related to Acquisition of:
	Arkis (1)		Derma Sciences (2)		ACell (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2024	$	15,755	$	2,557	$	300	$	68,700	87,312
Payment							(12,400)		(12,400)
Change in fair value of contingent consideration liabilities	(3,019)		137		—		3,100		218
Balance as of September 30, 2024	$	12,736	$	2,694	$	300	$	59,400	75,130

Short-Term - Accrued expenses and other liabilities	$	8,320	$	—	$	—	$	19,600	$	27,920
Long-Term - Other liabilities	4,416		2,694		300		39,800		47,210
Total	12,736		2,694		300		59,400		75,130

(1) Location in financial statements: Research and development

(2) Location in financial statements: Selling, general and administrative

Arkis BioSciences Inc.

As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10.0 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date. In the first quarter of 2025, the Company paid out a development milestone related to design verification procedures for $5.0 million.

Derma Sciences, Inc.

The Company assumed contingent consideration incurred by Derma Sciences, Inc. (“Derma Sciences”) related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. The Company accounted for the contingent liabilities by recording the fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains, which relates to net sales of Medihoney products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million.

ACell, Inc.

As part of the acquisition of ACell, the Company is required to make payments to the former shareholders of ACell up to $100.0 million in total for years 2022, 2023, and 2025 based on the achievement by the Company of certain revenue-based performance milestones. The Company estimated the fair value of the contingent consideration to be $23.9 million at the acquisition date. The 2022 and 2023 milestones were not achieved, leaving only one contingent milestone remaining. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone.

Surgical Innovations Associates, Inc.

As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $90.0 million for two separate payments, which are dependent on (1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as (2) the approval by the FDA of the pre-market approval ("PMA") application for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone at the acquisition date. In the second quarter of 2025, the Company paid out $18.1 million related to the 2024 performance year. Similarly, in the second quarter of 2024, the Company paid out $12.4 million related to the 2023 performance year. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The liability was adjusted in the third quarter of 2025 due to risk and uncertainty around timing of receiving the PMA approval.

LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 17,729	$ 18,255
ROU assets obtained in exchange for lease liabilities, net of modifications:
Operating leases	$ 6,493	$ 1,575

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Carrying Amount of Goodwill

Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2025 were as follows:


Dollars in thousands	Codman Specialty Surgical		Tissue Technologies		Total
Goodwill at December 31, 2024	$	715,730	$	381,222	$	1,096,952
Impairment	(388,106)		(123,259)		(511,365)
Foreign currency translation	16,567		13,045		29,612
Goodwill at September 30, 2025	$	344,191	$	271,008	$	615,199

Schedule of Finite-Lived Intangible Assets

The components of the Company’s identifiable intangible assets were as follows:


	September 30, 2025
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	17 years	$	1,484,605	$	(608,295)	$	876,310
Customer relationships	12 years	169,246		(143,789)		25,457
Trademarks/brand names	27 years	103,340		(46,639)		56,701
Codman tradename	Indefinite	179,516		—		179,516
Supplier relationships	30 years	30,211		(19,860)		10,351
All other	6 years	23,428		(11,618)		11,810
		$	1,990,346	$	(830,201)	$	1,160,145


	December 31, 2024
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	17 years	$	1,452,545	$	(525,959)	$	926,586
Customer relationships	12 years	166,038		(137,186)		28,852
Trademarks/brand names	27 years	99,951		(42,173)		57,778
Codman tradename	Indefinite	168,202		—		168,202
Supplier relationships	30 years	30,211		(19,126)		11,085
All other	6 years	22,820		(7,735)		15,085
		$	1,939,767	$	(732,179)	$	1,207,588

Schedule of Indefinite-Lived Intangible Assets

The components of the Company’s identifiable intangible assets were as follows:


	September 30, 2025
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	17 years	$	1,484,605	$	(608,295)	$	876,310
Customer relationships	12 years	169,246		(143,789)		25,457
Trademarks/brand names	27 years	103,340		(46,639)		56,701
Codman tradename	Indefinite	179,516		—		179,516
Supplier relationships	30 years	30,211		(19,860)		10,351
All other	6 years	23,428		(11,618)		11,810
		$	1,990,346	$	(830,201)	$	1,160,145


	December 31, 2024
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	17 years	$	1,452,545	$	(525,959)	$	926,586
Customer relationships	12 years	166,038		(137,186)		28,852
Trademarks/brand names	27 years	99,951		(42,173)		57,778
Codman tradename	Indefinite	168,202		—		168,202
Supplier relationships	30 years	30,211		(19,126)		11,085
All other	6 years	22,820		(7,735)		15,085
		$	1,939,767	$	(732,179)	$	1,207,588

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

DEBT - Contractual Maturity Table (Details) $ in Thousands	Sep. 30, 2025 USD ($)
Debt Disclosure [Abstract]
Remainder of 2025	$ 9,688
2026	38,750
2027	53,281
2028	634,531
Total long-term debt	$ 736,250

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-4

+ Details

INCOME TAXES - Summary of Effective Tax Rate (Details)	3 Months Ended		9 Months Ended
INCOME TAXES - Summary of Effective Tax Rate (Details)	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Reported tax rate	20.80%	47.50%	9.30%	35.30%

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)
Goodwill [Line Items]
Goodwill impairment charge	$ 0	$ 511,400,000	$ 0		$ 511,365,000	$ 0	$ 0
Amortization	26,900,000		25,600,000		80,100,000	78,700,000
Non-cash impairment charges					511,365,000	12,173,000
Expected annual amortization expense, remainder of 2025	26,900,000				26,900,000
Expected annual amortization expense, in 2026	107,600,000				107,600,000
Expected annual amortization expense, in 2027	106,500,000				106,500,000
Expected annual amortization expense, in 2028	103,000,000.0				103,000,000.0
Expected annual amortization expense, in 2029	97,700,000				97,700,000
Expected annual amortization expense, in 2030	91,600,000				91,600,000
Expected annual amortization expense, thereafter	447,600,000				447,600,000
Intangible assets, net	1,160,145,000				1,160,145,000		1,207,588,000
Completed technology
Goodwill [Line Items]
Cost, amortization	23,100,000		21,800,000		69,000,000.0	61,100,000
Completed technology \| Completed Technology, Surgimend
Goodwill [Line Items]
Intangible assets, net	27,400,000				27,400,000
Completed technology \| Completed Technology, PriMatrix
Goodwill [Line Items]
Intangible assets, net	$ 21,100,000				$ 21,100,000
Customer Relationships
Goodwill [Line Items]
Non-cash impairment charges			$ 7,100,000	$ 7,100,000		$ 7,100,000
Codman tradename
Goodwill [Line Items]
Impairment of indefinite-lived intangible assets		0					$ 0
Tissue Technologies
Goodwill [Line Items]
Goodwill impairment charge		123,300,000
Neurosurgery
Goodwill [Line Items]
Goodwill impairment charge		249,000,000.0
Instruments
Goodwill [Line Items]
Goodwill impairment charge		$ 139,100,000
Measurement Input, Long-Term Revenue Growth Rate \| Tissue Technologies \| Valuation Technique, Discounted Cash Flow
Goodwill [Line Items]
Reporting unit, measurement input		0.025
Measurement Input, Long-Term Revenue Growth Rate \| Neurosurgery \| Valuation Technique, Discounted Cash Flow
Goodwill [Line Items]
Reporting unit, measurement input		0.025
Measurement Input, Long-Term Revenue Growth Rate \| Instruments \| Valuation Technique, Discounted Cash Flow
Goodwill [Line Items]
Reporting unit, measurement input		0.025
Measurement Input, Discount Rate \| Valuation Technique, Discounted Cash Flow \| Codman tradename
Goodwill [Line Items]
Indefinite-lived intangible assets, measurement input		0.145
Measurement Input, Discount Rate \| Tissue Technologies \| Valuation Technique, Discounted Cash Flow
Goodwill [Line Items]
Reporting unit, measurement input		0.135
Measurement Input, Discount Rate \| Neurosurgery \| Valuation Technique, Discounted Cash Flow
Goodwill [Line Items]
Reporting unit, measurement input		0.135
Measurement Input, Discount Rate \| Instruments \| Valuation Technique, Discounted Cash Flow
Goodwill [Line Items]
Reporting unit, measurement input		0.120

INVENTORIES - Schedule of Net Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Finished goods	$ 258,774	$ 223,729
Work in process	100,010	79,423
Raw materials	130,322	125,938
Total inventories, net	$ 489,106	$ 429,090

DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Derivative Instruments, Gain (Loss) [Roll Forward]
Balance, beginning of period	$ 1,038,661	$ 1,534,195	$ 1,545,280	$ 1,587,884
Balance, end of period	1,037,574	1,521,587	1,037,574	1,521,587
Accumulated Other Comprehensive Loss
Derivative Instruments, Gain (Loss) [Roll Forward]
Balance, beginning of period	(30,907)	(18,726)	(27,571)	(15,106)
Balance, end of period	(31,975)	(24,854)	(31,975)	(24,854)
Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Roll Forward]
Amount of Gain (Loss) Recognized in AOCI	15,079	(54,335)	(102,549)	15,660
Amount of Gain (Loss) Reclassified from AOCI into Earnings	13,082	(15,334)	(25,144)	30,603
Designated as Hedging Instrument \| Accumulated Other Comprehensive Loss
Derivative Instruments, Gain (Loss) [Roll Forward]
Balance, beginning of period	(73,983)	6,353	5,419	(17,705)
Balance, end of period	(71,986)	(32,648)	(71,986)	(32,648)
Designated as Hedging Instrument \| Interest rate swap \| Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Roll Forward]
Balance, beginning of period	35,051	53,116	48,794	43,556
Amount of Gain (Loss) Recognized in AOCI	1,253	(17,133)	(9,630)	2,678
Amount of Gain (Loss) Reclassified from AOCI into Earnings	4,629	4,135	7,489	14,386
Balance, end of period	31,675	31,848	31,675	31,848
Designated as Hedging Instrument \| Cross-currency swap \| Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Roll Forward]
Balance, beginning of period	(14,767)	(16,867)	(11,621)	(15,763)
Amount of Gain (Loss) Recognized in AOCI	9,033	(16,625)	(40,504)	13,505
Amount of Gain (Loss) Reclassified from AOCI into Earnings	5,046	(22,089)	(41,345)	9,145
Balance, end of period	(10,780)	(11,403)	(10,780)	(11,403)
Designated as Hedging Instrument \| Cross-currency swap \| Net Investment Hedges
Derivative Instruments, Gain (Loss) [Roll Forward]
Balance, beginning of period	(96,173)	(29,466)	(31,130)	(45,498)
Amount of Gain (Loss) Recognized in AOCI	4,955	(21,051)	(54,356)	(364)
Amount of Gain (Loss) Reclassified from AOCI into Earnings	3,407	2,739	9,139	7,394
Balance, end of period	(94,625)	(53,256)	(94,625)	(53,256)
Designated as Hedging Instrument \| Foreign currency forward contract \| Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Roll Forward]
Balance, beginning of period	1,906	(430)	(624)	0
Amount of Gain (Loss) Recognized in AOCI	(162)	474	1,941	(159)
Amount of Gain (Loss) Reclassified from AOCI into Earnings	0	(119)	(427)	(322)
Balance, end of period	$ 1,744	$ 163	$ 1,744	$ 163

DEBT

9 Months Ended

Sep. 30, 2025

Debt Disclosure [Abstract]

DEBT

Amendment to the Seventh Amended and Restated Credit Agreement

On June 6, 2025, in response to the risks and uncertainties surrounding the Company’s future results of operations due to tariffs, the Company entered into the June 2025 Amendment of the Senior Credit Facility with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The June 2025 Amendment did not increase the Company’s total indebtedness or extend the maturity date of the Senior Credit Facility.

Under the terms of the June 2025 Amendment, the Company’s Consolidated Total Leverage Ratio (defined, as of any date of determination, as the ratio of (a) Consolidated Funded Indebtedness as of such date (as defined in the Senior Credit Facility) less cash that is not subject to any restriction on the use or investment thereof to (b) Consolidated EBITDA (as defined in the Senior Credit Facility)) for the period of four consecutive fiscal quarters ending on such date was modified to the following:


Fiscal Quarter Ending						Maximum Consolidated Total Leverage Ratio
June 30, 2025 through June 30, 2026						5.00 to 1.00
September 30, 2026						4.75 to 1.00
December 31, 2026						4.50 to 1.00
March 31, 2027 and the last day of each fiscal quarter thereafter						4.00 to 1.00

In addition to the foregoing, from the date of the June 2025 Amendment through the fiscal quarter ending December 31, 2026 (the “Covenant Relief Period”), the Amendment, among other things, also: (i) temporarily establishes, during the Covenant Relief Period, a revised applicable rate schedule; (ii) temporarily limits, during the Covenant Relief Period, the Company’s ability to make certain investments; (iii) temporarily restricts, during the Covenant Relief Period, the Company’s ability to incur incremental indebtedness under the Senior Credit Facility, create certain liens, make certain restricted payments and incur or guarantee indebtedness of excluded subsidiaries; and (iv) temporarily prohibits, during the Covenant Relief Period, the Company from selling, transferring or exclusively licensing material intellectual property to a subsidiary of the Company that is not a loan party under the Senior Credit Facility or designating any subsidiary that owns or exclusively licenses any material intellectual property as an excluded subsidiary under the Senior Credit Facility.

Borrowings under the Senior Credit Facility bear interest under the applicable rate schedule, at the Company’s option, at a rate equal to the following:

i.Term SOFR in effect from time to time plus 0.10% plus the applicable rate (ranging from 1.00% to 2.13% during the Covenant Relief Period and from 1.00% to 1.75% thereafter) or

ii.The highest of:

1.the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%;

2.the prime lending rate of Bank of America, N.A.; or

3.the one-month Term SOFR plus 1.00%.

The applicable rates are based on the Company’s Consolidated Total Leverage Ratio for the period of four consecutive fiscal quarters ending on such date.

The Company will pay an annual commitment fee (ranging from 0.15% to 0.33% during the Covenant Relief Period and from 0.15% to 0.30% thereafter), based on the Company’s Consolidated Total Leverage Ratio, on the amount available for borrowing under the revolving credit facility component of the Senior Credit Facility.

In connection with the June 2025 Amendment, the Company incurred $3.9 million in fees to creditors and third parties.

On March 24, 2023, the Company entered into the Senior Credit Facility with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The Senior Credit Facility extended the maturity date to March 24, 2028, amended the contractual repayments of the term loan component, and amended the interest rate from LIBOR to SOFR-indexed interest.

The Company continues to have the aggregate principal amount of up to approximately $2.1 billion available to it through the following facilities: (i) a $775 million term loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans. The terms of the Senior Credit Facility limit the amount of dividends the Company may pay.

The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and, at September 30, 2025, the Company was in compliance with all such covenants.

At September 30, 2025 and December 31, 2024, there was $1.0 billion and $365.0 million, respectively, outstanding under the revolving credit facility component of the Senior Credit Facility. At September 30, 2025 and December 31, 2024, there was $736.3 million and $760.5 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 6.4% and 6.0%, respectively. As of September 30, 2025 and December 31, 2024 there was $38.8 million and $33.9 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.

The fair value of the term loan component and revolving credit facility component of the Senior Credit Facility at September 30, 2025 was $734.0 million, and $1,011.6 million, respectively. The fair value was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.

As of September 30, 2025 and December 31, 2024, letters of credit outstanding totaled $3.0 million and $1.7 million, respectively. There were no amounts drawn under the letters of credit outstanding as of September 30, 2025.

Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:


As of September 30, 2025	Principal Repayment
Dollars in thousands
Remainder of 2025	$	9,688
2026	38,750
2027	53,281
2028	634,531

	$	736,250

Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $11.8 million for the remainder of 2025, $45.5 million in 2026, $42.8 million in 2027, and $9.3 million in 2028. Interest is calculated on the term loan component of the Senior Credit Facility based on SOFR plus the certain amounts set forth in the Senior Credit Facility. As the revolving credit facility component of the Senior Credit Facility and Securitization Facility (defined below) can be repaid at any time, no interest has been included in the calculation.

Any outstanding borrowings on the revolving credit facility component of the Senior Credit Facility are due on March 24, 2028.

Convertible Senior Notes

The Company’s 0.5% Convertible Senior Notes due 2025 (the “2025 Notes”) issued in February 2020 pursuant to an indenture, dated as of February 7, 2020 (the “Original Indenture”), between the Company and Citibank, N.A., as trustee, matured on August 15, 2025. The 2025 Notes were settled upon maturity for $575.0 million in cash, excluding accrued interest, funded by borrowings on the revolving credit facility component of the Senior Credit Facility. No shares were issued to settle the 2025 Notes.

In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments. The call transactions entered into with the hedge participants expired in August 2025 and the warrant transactions entered into with the hedge participants expire ratably over the period from November 2025 through February 2026.

Securitization Facility

The Company maintains an accounts receivable securitization facility (the “Securitization Facility”) under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement (“Securitization Agreement”) governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of September 30, 2025, the Company was in compliance with the covenants and none of the termination events had occurred.

On December 15, 2023, the Company entered into an amendment (the “December 2023 Amendment”) of the Securitization Facility which extended the maturity date from May 28, 2024 to December 15, 2026. The Company incurred approximately $0.3 million of new issuance costs associated with the December 2023 Amendment which will be amortized over 3 years, the length of the Securitization Agreement as amended by the December 2023 Amendment. Due to the increase in borrowing capacity, the remaining $0.1 million of unamortized costs from the previous agreement will also be amortized over the length of the amended agreement, three years. In addition, on April 17, 2023 the Company entered into an amendment (the “April 2023 Amendment”) of the Securitization Facility and amended the interest rate from LIBOR to SOFR-indexed rate. The December 2023 Amendment and April 2023 Amendment did not increase the Company’s total indebtedness.

At September 30, 2025 and December 31, 2024, the Company had $83.5 million and $108.1 million, respectively, of outstanding borrowings under its Securitization Facility with an interest rate of 5.2% and 5.4%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at September 30, 2025 was $82.0 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.

Debt Issuance Costs

Debt issuance costs associated with the Senior Credit Facility (other than the revolving credit facility component) and the 2025 Notes are presented as a reduction to the carrying value of the related debt. Debt issuance costs associated with the revolving credit facility component of the Senior Credit Facility are capitalized within other long-term assets on the consolidated balance sheet.

Estimated Fair Value of Debt Measurements

The carrying amounts and the estimated fair values of debt as of September 30, 2025 and December 31, 2024 are as follows:


		September 30, 2025				December 31, 2024
	Fair Value Measurement	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
Dollars in thousands
Senior credit facility - term loan	Level 2	$	736,250	$	733,980	$	760,469	$	751,143
Senior credit facility - revolving component	Level 2	1,015,000		1,011,573		365,000		360,144
2025 Notes	Level 1	—		—		575,000		555,594
Securitization	Level 2	83,500		82,046		108,100		105,831
Subtotal		$	1,834,750	$	1,827,599	$	1,808,569	$	1,772,712
Debt issuance costs		(3,649)				(5,476)
Total debt		$	1,831,101	$	1,827,599	$	1,803,093	$	1,772,712

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2025

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate

The following table provides a summary of the Company’s effective tax rate:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Reported tax rate	20.8	%	47.5	%	9.3	%	35.3	%

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2025	Oct. 29, 2025
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2025
Document Transition Report	false
Entity File Number	000-26224
Entity Registrant Name	INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	51-0317849
Entity Address	1100 Campus Road
Entity City	Princeton
Entity State	NJ
Entity Postal Zip Code	08540
City Area Code	609
Local Phone Number	275-0500
Title of 12(b) Security	Common Stock, Par Value $.01 Per Share
Trading Symbol	IART
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		77,892,111
Amendment Flag	false
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000917520
Current Fiscal Year End Date	--12-31

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SEGMENT AND GEOGRAPHIC INFORMATION - Revenue by Major Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting Information [Line Items]
Total Revenues	$ 402,062	$ 380,834	$ 1,200,320	$ 1,167,881
United States
Segment Reporting Information [Line Items]
Total Revenues	295,846	290,192	884,371	856,646
Europe
Segment Reporting Information [Line Items]
Total Revenues	42,893	34,368	120,813	116,653
Asia Pacific
Segment Reporting Information [Line Items]
Total Revenues	42,680	37,052	135,517	132,548
Rest of World
Segment Reporting Information [Line Items]
Total Revenues	$ 20,643	$ 19,222	$ 59,619	$ 62,034

- Definition

+ References

+ Details

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2025

Inventory Disclosure [Abstract]

Schedule of Inventories, Net

Inventories, net consisted of the following:


Dollars in thousands	September 30, 2025		December 31, 2024
Finished goods	$	258,774	$	223,729
Work in process	100,010		79,423
Raw materials	130,322		125,938
Total inventories, net	$	489,106	$	429,090

SEGMENT AND GEOGRAPHIC INFORMATION

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

The Company is organized primarily on the basis of products and operates two global reportable segments. Resources are allocated and performance is assessed by the Company’s President and Chief Executive Officer, which the Company has determined to be the Chief Operating Decision Maker (“CODM”).

The two reportable segments and their activities are described below.

•The Codman Specialty Surgical segment operations consist of (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices; and (iii) the ENT business, which includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, as well as surgical navigation systems.

•The Tissue Technologies segment operations consists of Wound Reconstruction and Care business, which sells offerings such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. The Tissue Technologies segment also includes the Company’s private label business.

The Corporate and Other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs, which are not allocated to the reportable segments.

For both segments, the CODM uses segment revenue and segment operating income to assess the performance for each segment and in the annual budgeting and forecasting process. The CODM considers budget-to-actual variances on a quarterly basis for segment revenue and segment operating income when making decisions about allocating capital and personnel to the segments.

The operating results of the reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the reportable segments.

Net sales and profit by each reportable segment for the three and nine months ended September 30, 2025 and 2024 are as follows:


	Three Months Ended September 30, 2025								Nine Months Ended September 30, 2025
Dollars in thousands	Codman Specialty Surgical		Tissue Technologies		Corporate and Other		Total		Codman Specialty Surgical		Tissue Technologies		Corporate and Other		Total
Total revenue, net	$	292,583	$	109,479	$	—	$	402,062	$	877,204	$	323,116	$	—	$	1,200,320

Cost of goods sold	93,289		42,668		59,114		195,071		288,070		138,499		162,996		589,565
Research and development	6,632		4,189		11,635		22,456		22,276		12,243		39,662		74,181
Selling, general & administrative	62,433		35,478		71,135		169,046		201,309		110,283		218,841		530,433
Intangible asset amortization	—		—		3,728		3,728		—		—		11,186		11,186
Goodwill impairment	—		—		—		—		388,106		123,259		—		511,365
Total cost and expenses	162,354		82,335		145,612		390,301		899,761		384,284		432,685		1,716,730

Operating income (loss)	$	130,229	$	27,144	$	(145,612)	11,761		$	(22,557)	$	(61,168)	$	(432,685)	(516,410)
Interest income							4,982								14,112
Interest expense							(22,725)								(62,582)
Other income, net							(842)								(2,932)
Loss before income taxes							$	(6,824)							$	(567,812)


	Three Months Ended September 30, 2024								Nine Months Ended September 30, 2024
Dollars in thousands	Codman Specialty Surgical		Tissue Technologies		Corporate and Other		Total		Codman Specialty Surgical		Tissue Technologies		Corporate and Other		Total
Total revenue, net	$	270,782	$	110,052	$	—	$	380,834	$	828,977	$	338,904	$	—	$	1,167,881

Cost of goods sold	95,829		40,529		44,238		180,596		281,443		119,512		133,937		534,892
Research and development	8,548		4,506		14,381		27,435		21,880		13,858		48,429		84,167
Selling, general & administrative	65,867		36,535		74,791		177,193		157,483		109,199		271,781		538,463
Intangible asset amortization	—		—		3,760		3,760		—		—		17,575		17,575

Total cost and expenses	170,244		81,570		137,170		388,984		460,806		242,569		471,722		1,175,097

Operating income (loss)	$	100,538	$	28,482	$	(137,170)	(8,150)		$	368,171	$	96,335	$	(471,722)	(7,216)
Interest income							5,049								15,147
Interest expense							(19,373)								(51,648)
Other income, net							2,112								2,939
Loss before income taxes							$	(20,362)							$	(40,778)

The Company does not allocate any assets to the reportable segments. No asset information is reported to the CODM and disclosed in the financial information for each segment. The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:


	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in thousands	2025		2024		2025		2024
United States	$	295,846	$	290,192	$	884,371	$	856,646
Europe	42,893		34,368		120,813		116,653
Asia Pacific	42,680		37,052		135,517		132,548
Rest of World	20,643		19,222		59,619		62,034
Total Revenues	$	402,062	$	380,834	$	1,200,320	$	1,167,881

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

STOCK-BASED COMPENSATION (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2025 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period, net of forfeitures (in shares) \| shares	395,252
Options, weighted average grant date fair value (in dollars per share) \| $ / shares	$ 10.77
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs \| $	$ 4.9
Weighted-average period for cost recognition	3 years
Stock Options \| Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period	1 year
Stock Options \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	8 years
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period	3 years
Total unrecognized compensation costs \| $	$ 33.0
Weighted-average period for cost recognition	2 years
Awards granted during the period (in shares) \| shares	1,012,799
Other than options, weighted average grant date fair value (in dollars per share) \| $ / shares	$ 21.09
Performance Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period	3 years
Awards granted during the period (in shares) \| shares	395,781
Other than options, weighted average grant date fair value (in dollars per share) \| $ / shares	$ 23.95
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period	3 years
Maximum \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period	4 years
Maximum \| Stock Options \| Directors and Certain Executive Officers
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Minimum \| Stock Options \| Directors and Certain Executive Officers
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	6 years

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance	$ 5,637	$ 6,917
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, authorized shares (in shares)	15,000,000	15,000,000
Preferred stock, outstanding shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized shares (in shares)	240,000,000	240,000,000
Common stock, issued shares (in shares)	92,251,000	91,610,000
Treasury stock outstanding (in shares)	14,416,000	14,445,000

ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Equity [Abstract]
Net loss	$ (5,404)	$ (484,073)	$ (25,293)	$ (10,695)	$ (12,402)	$ (3,281)	$ (514,770)	$ (26,379)
Foreign currency translation adjustment	(1,701)			5,386			6,484	(2,558)
Change in unrealized (gain) loss on derivatives, net of tax	800			(11,044)			(10,405)	(6,714)
Pension liability adjustment, net of tax	(167)			(470)			(483)	(475)
Comprehensive loss, net	$ (6,472)			$ (16,823)			$ (519,174)	$ (36,126)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period	$ 1,038,661	$ 1,524,139	$ 1,545,280	$ 1,534,195	$ 1,597,952	$ 1,587,884	$ 1,545,280
Other comprehensive (loss) gain							(27,637)
Less: Amounts reclassified from accumulated other comprehensive income, net							(23,233)
Net current-period other comprehensive (loss) gain	(1,068)	(6,801)	3,465	(6,128)	(8,080)	4,460	(4,404)
Balance, end of period	1,037,574	1,038,661	1,524,139	1,521,587	1,534,195	1,597,952	1,037,574
Total
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period	(30,907)	(24,106)	(27,571)	(18,726)	(10,646)	(15,106)	(27,571)
Net current-period other comprehensive (loss) gain	(1,068)	(6,801)	3,465	(6,128)	(8,080)	4,460
Balance, end of period	(31,975)	$ (30,907)	(24,106)	$ (24,854)	$ (18,726)	$ (10,646)	(31,975)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period			26,612				26,612
Other comprehensive (loss) gain							(41,147)
Less: Amounts reclassified from accumulated other comprehensive income, net							(30,742)
Net current-period other comprehensive (loss) gain							(10,405)
Balance, end of period	16,207						16,207
Defined Benefit Pension Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period			4,028				4,028
Other comprehensive (loss) gain
Less: Amounts reclassified from accumulated other comprehensive income, net							483
Net current-period other comprehensive (loss) gain							(483)
Balance, end of period	3,545						3,545
Foreign Currency Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period			$ (58,211)				(58,211)
Other comprehensive (loss) gain							13,510
Less: Amounts reclassified from accumulated other comprehensive income, net							7,026
Net current-period other comprehensive (loss) gain							6,484
Balance, end of period	$ (51,727)						$ (51,727)

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

RETIREMENT PLANS	9 Months Ended
RETIREMENT PLANS	Sep. 30, 2025
Retirement Benefits [Abstract]
RETIREMENT PLANS	RETIREMENT PLANS The Company has various defined benefit plans which cover certain employees in France, Japan, Germany and Switzerland. Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2025 were $0.4 million and $1.1 million. The components of the net periodic benefit costs other than the service cost component of $0.8 million and $2.5 million for the three and nine months ended September 30, 2025 are included in other income, net in the consolidated statements of operations. Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2024 were $0.4 million and $1.3 million. The components of the net periodic benefit costs other than the service cost component of $0.8 million and $2.4 million for the three and nine months ended September 30, 2024 are included in other income, net in the consolidated statements of operations. The estimated fair values of plan assets were $61.6 million and $51.8 million as of September 30, 2025 and December 31, 2024, respectively. The net plan assets of the pension plans are invested in common trusts as of September 30, 2025 and December 31, 2024. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile. Deferred Compensation Plan The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation. This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets were $7.6 million and $6.7 million as of September 30, 2025 and December 31, 2024, respectively. Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details

ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($) $ in Millions			1 Months Ended		6 Months Ended
	Oct. 02, 2024	Apr. 01, 2024	Oct. 31, 2026	Oct. 30, 2025	Dec. 31, 2024
Acclarent Inc.
Business Combination [Line Items]
Purchase price of business combination		$ 282.0
Final working capital adjustment					$ 4.2
Business combination, recognize deferred tax liabilities					$ 1.1
Estimated useful life		11 years
Discount rate		12.20%
Durepair Regeneration Matrix
Business Combination [Line Items]
Upfront payment	$ 45.0
Payments for asset acquisitions	$ 10.0
Durepair Regeneration Matrix \| Forecast
Business Combination [Line Items]
Payments for asset acquisitions			$ 20.0	$ 15.0

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Changes in Contract Assets and Contract Liabilities

The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2025:




Dollars in thousands	Total
Contract Asset
Contract asset, January 1, 2025	$	6,146
Transferred to trade receivables from contract asset included in beginning of the year contract asset	$	(6,146)

Contract asset, net of transferred to trade receivables on contracts during the period	$	4,928
Contract asset, September 30, 2025	$	4,928

Contract Liability
Contract liability, January 1, 2025	$	19,669
Recognition of revenue included in beginning of year contract liability	$	(8,452)

Contract liability, net of revenue recognized on contracts during the period	$	11,008
Foreign currency translation	$	123
Contract liability, September 30, 2025	$	22,348

Schedule of Disaggregation of Revenue

The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2025 and 2024 (dollar amounts in thousands):


	Three Months Ended September 30, 2025		Three Months Ended September 30, 2024		Nine Months Ended September 30, 2025		Nine Months Ended September 30, 2024
Neurosurgery	$	201,563	$	175,956	$	601,466	$	583,726
Instruments	50,151		54,238		154,181		153,148
ENT	40,869		40,588		121,557		92,103
Total Codman Specialty Surgical	292,583		270,782		877,204		828,977

Wound Reconstruction and Care	83,988		80,460		243,514		249,032
Private Label	25,491		29,592		79,602		89,872
Total Tissue Technologies	109,479		110,052		323,116		338,904
Total revenue	$	402,062	$	380,834	$	1,200,320	$	1,167,881

NET LOSS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2025

Earnings Per Share [Abstract]

Basic and Diluted Net Income (Loss) Per Share

Basic and diluted net loss per share was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in thousands, except per share amounts	2025		2024		2025		2024
Basic net loss per share:
Net loss	$	(5,404)	$	(10,695)	$	(514,770)	$	(26,379)
Weighted average common shares outstanding	76,753		76,448		76,637		77,196

Basic net loss per common share	$	(0.07)	$	(0.14)	$	(6.72)	$	(0.34)

Diluted net loss per share:
Net loss	$	(5,404)	$	(10,695)	$	(514,770)	$	(26,379)

Weighted average common shares outstanding — Basic	76,753		76,448		76,637		77,196
Effect of dilutive securities:
Stock options and restricted stock	—		—		—		—
Weighted average common shares for diluted earnings per share	76,753		76,448		76,637		77,196

Diluted net loss per common share	$	(0.07)	$	(0.14)	$	(6.72)	$	(0.34)

COMMITMENTS AND CONTINGENCIES (Fair Value Contingent Consideration) (Details) - Contingent Consideration Liability - Level 3 - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 69,657	$ 87,312
Payment	(23,075)	(12,400)
Change in fair value of contingent consideration liabilities	(14,644)	218
Balance, end of period	31,938	75,130
Short-Term - Accrued expenses and other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	25,403	27,920
Long-Term - Other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	6,535	47,210
Arkis
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	12,968	15,755
Payment	(5,000)
Change in fair value of contingent consideration liabilities	(1,770)	(3,019)
Balance, end of period	6,198	12,736
Arkis \| Short-Term - Accrued expenses and other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	0	8,320
Arkis \| Long-Term - Other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	6,198	4,416
Derma Sciences
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	2,686	2,557
Payment	0
Change in fair value of contingent consideration liabilities	(2,349)	137
Balance, end of period	337	2,694
Derma Sciences \| Short-Term - Accrued expenses and other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	0	0
Derma Sciences \| Long-Term - Other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	337	2,694
ACell
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	3	300
Payment	0
Change in fair value of contingent consideration liabilities	0	0
Balance, end of period	3	300
ACell \| Short-Term - Accrued expenses and other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	3	0
ACell \| Long-Term - Other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	0	300
Surgical Innovation Associates, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	54,000	68,700
Payment	(18,075)	(12,400)
Change in fair value of contingent consideration liabilities	(10,525)	3,100
Balance, end of period	25,400	59,400
Surgical Innovation Associates, Inc. \| Short-Term - Accrued expenses and other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	25,400	19,600
Surgical Innovation Associates, Inc. \| Long-Term - Other liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, end of period	$ 0	$ 39,800

DEBT (Tables)

9 Months Ended

Sep. 30, 2025

Debt Disclosure [Abstract]

Schedule of Long-term Debt Maximum Leverage Ratios


Fiscal Quarter Ending						Maximum Consolidated Total Leverage Ratio
June 30, 2025 through June 30, 2026						5.00 to 1.00
September 30, 2026						4.75 to 1.00
December 31, 2026						4.50 to 1.00
March 31, 2027 and the last day of each fiscal quarter thereafter						4.00 to 1.00

Schedule of Contractual Repayments of Long-Term Debt

Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:


As of September 30, 2025	Principal Repayment
Dollars in thousands
Remainder of 2025	$	9,688
2026	38,750
2027	53,281
2028	634,531

	$	736,250

Schedule of Carrying Amounts and Estimated Fair Values of Debt Instruments

The carrying amounts and the estimated fair values of debt as of September 30, 2025 and December 31, 2024 are as follows:


		September 30, 2025				December 31, 2024
	Fair Value Measurement	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
Dollars in thousands
Senior credit facility - term loan	Level 2	$	736,250	$	733,980	$	760,469	$	751,143
Senior credit facility - revolving component	Level 2	1,015,000		1,011,573		365,000		360,144
2025 Notes	Level 1	—		—		575,000		555,594
Securitization	Level 2	83,500		82,046		108,100		105,831
Subtotal		$	1,834,750	$	1,827,599	$	1,808,569	$	1,772,712
Debt issuance costs		(3,649)				(5,476)
Total debt		$	1,831,101	$	1,827,599	$	1,803,093	$	1,772,712

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Operating Leased Assets [Line Items]
Remainder of 2025	$ 5,772
2026	17,620
2027	20,916
2028	18,483
2029	18,115
2030	17,642
Thereafter	163,525
Total minimum lease payments	262,073
Less: Imputed interest	87,314
Total lease liabilities	174,759	$ 181,470
Less: Current lease liabilities	13,826	14,540
Long-term lease liabilities	160,933	$ 166,930
Related Parties
Operating Leased Assets [Line Items]
Remainder of 2025	74
2026	296
2027	296
2028	296
2029	246
2030	0
Thereafter	0
Total minimum lease payments	1,208
Third Parties
Operating Leased Assets [Line Items]
Remainder of 2025	5,698
2026	17,324
2027	20,620
2028	18,187
2029	17,869
2030	17,642
Thereafter	163,525
Total minimum lease payments	$ 260,865

LEASES AND RELATED PARTY LEASES - Narrative (Details)	9 Months Ended
LEASES AND RELATED PARTY LEASES - Narrative (Details)	Sep. 30, 2025 USD ($) renewalOption	Sep. 30, 2024 USD ($)
Operating Leased Assets [Line Items]
Number of renewal options (or more) \| renewalOption	1
Operating lease expense	$ 17,800,000	$ 18,800,000
Future minimum lease payments, finance leases	0
Related Party
Operating Leased Assets [Line Items]
Operating lease expense	$ 200,000	$ 200,000
Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director	50.00%
Annual rate of lease agreement	$ 300,000
Related Party \| Five Year Option Lease Period One
Operating Leased Assets [Line Items]
Period for extended lease	November 1, 2029 through October 31, 2034
Related Party \| Five Year Option Lease Period Two
Operating Leased Assets [Line Items]
Option to extend lease, years	5 years
Period for extended lease	November 1, 2034 through October 31, 2039
Affiliated Entity \| Five Year Option Lease Period One
Operating Leased Assets [Line Items]
Option to extend lease, years	5 years

GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Intangible Asset, Acquired, Finite-Lived [Line Items]
Cost	$ 1,990,346	$ 1,939,767
Accumulated Amortization	(830,201)	(732,179)
Net	1,160,145	1,207,588
Codman tradename
Intangible Asset, Acquired, Finite-Lived [Line Items]
Cost	179,516	168,202
Net	$ 179,516	$ 168,202
Completed technology
Intangible Asset, Acquired, Finite-Lived [Line Items]
Weighted Average Life	17 years	17 years
Cost	$ 1,484,605	$ 1,452,545
Accumulated Amortization	(608,295)	(525,959)
Net	$ 876,310	$ 926,586
Customer relationships
Intangible Asset, Acquired, Finite-Lived [Line Items]
Weighted Average Life	12 years	12 years
Cost	$ 169,246	$ 166,038
Accumulated Amortization	(143,789)	(137,186)
Net	$ 25,457	$ 28,852
Trademarks/brand names
Intangible Asset, Acquired, Finite-Lived [Line Items]
Weighted Average Life	27 years	27 years
Cost	$ 103,340	$ 99,951
Accumulated Amortization	(46,639)	(42,173)
Net	$ 56,701	$ 57,778
Supplier relationships
Intangible Asset, Acquired, Finite-Lived [Line Items]
Weighted Average Life	30 years	30 years
Cost	$ 30,211	$ 30,211
Accumulated Amortization	(19,860)	(19,126)
Net	$ 10,351	$ 11,085
All other
Intangible Asset, Acquired, Finite-Lived [Line Items]
Weighted Average Life	6 years	6 years
Cost	$ 23,428	$ 22,820
Accumulated Amortization	(11,618)	(7,735)
Net	$ 11,810	$ 15,085

BASIS OF PRESENTATION - Schedule of Restructuring Charges (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Restructuring Reserve [Roll Forward]
Balance, beginning of the year	$ 5,151	$ 2,113
Payments and other adjustments	(8,129)	(1,691)
Balance, end of the period	4,332	422
Cost of Goods Sold
Restructuring Reserve [Roll Forward]
Charges	$ 113	$ 0
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of goods sold	Cost of goods sold
Research and development
Restructuring Reserve [Roll Forward]
Charges	$ 417	$ 0
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Research and development	Research and development
Selling, general and administrative
Restructuring Reserve [Roll Forward]
Charges	$ 6,780	$ 0
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative	Selling, general and administrative

- Definition

Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References + Details

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2025

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FASB Topic 820, Fair Value Measurement (“ASC 820”) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability.

Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three-level hierarchy of the inputs (i.e., assumptions that market participants would use in pricing an asset or liability) used to measure fair value, giving the highest priority to quoted prices in active markets and the lowest priority to unobservable inputs in measuring fair value. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the entire fair value measurement. The three levels of the valuation hierarchy are defined as follows:

Level 1: Inputs to the valuation methodology are quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Inputs to the valuation methodology are unobservable inputs that are supported by little or no market activity and are based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company has investments in time deposits that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, as well as certain debt obligations that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The investments in time deposits are classified as cash and cash equivalents and short-term investments on the consolidated balance sheets which is determined based on maturities at the time of purchase and re-evaluated at each balance sheet date.

The Company also has investments in derivative instruments, which are comprised of interest rate swaps, cross currency swaps, net investment hedges, and forward foreign currency contracts that are classified within Level 2 of the fair value hierarchy because they are valued using analyses obtained from independent third-party valuation specialists based on market observable inputs. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 7. Derivative Instruments for further discussion and information on these derivative contracts.

In addition, the Company has contingent consideration liabilities that are classified within Level 3 of the fair value hierarchy because they are measured at fair value using significant unobservable inputs, including management’s forecast of future revenues for the acquired businesses as well as management’s estimates of the likelihood of achieving the other specified criteria. Refer to Note 16. Commitments and Contingencies for additional information on these contingent consideration liabilities.

Assets and liabilities measured and recorded at fair value on a recurring basis as of September 30, 2025 and December 31, 2024 consisted of the following:


Dollars in thousands	Fair Value Measurement	September 30, 2025		December 31, 2024
Assets:
Cash and cash equivalents	Level 1	$	232,186	$	246,375
Short-term investments	Level 1	35,693		27,192
Interest rate swaps	Level 2	31,673		48,795

Foreign currency forward contracts	Level 2	309		—
Foreign currency forward contracts (not designated as hedges)	Level 2	933		1,700
Total Assets:		$	300,794	$	324,062

Liabilities:
Cross currency rate swaps	Level 2	$	57,034	$	4,367
Net investment hedges	Level 2	94,174		31,113
Foreign currency forward contracts	Level 2	—		914
Contingent consideration	Level 3	31,938		69,657

Total Liabilities:		$	183,146	$	106,051

There were no transfers into or out of Level 3 during the three and nine months ended September 30, 2025 and 2024.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

The Company remeasures the fair value of certain assets and liabilities, including property, plant and equipment, operating lease - right of use assets, and goodwill and other intangible assets, upon the occurrence of certain events. The amounts recognized were recorded to remeasure the carrying amount of assets to the assets’ fair values, which were generally estimated, based upon a market participant’s perspective, using Level 3 measurements, including values estimated using the income approach.

Other than the fair value estimates disclosed in Note 2. Acquisitions and Divestitures, Note 5. Goodwill and Other Intangible Assets, and Note 10. Leases and Related Party Leases, there were no non-recurring fair value measurements during the three and nine months ended September 30, 2025 and 2024.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

RETIREMENT PLANS (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
RETIREMENT PLANS (Details) - USD ($) $ in Millions	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Retirement Benefits [Abstract]
Net periodic benefit costs	$ 0.4	$ 0.4	$ 1.1	$ 1.3
Service cost component	0.8	$ 0.8	2.5	$ 2.4
Estimated fair value of plan assets	61.6		$ 61.6		$ 51.8
Defer payment and taxation, base salary, percentage (up to)			75.00%
Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to)			100.00%
Deferred compensation plan, fair value of assets	$ 7.6		$ 7.6		$ 6.7

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details

REVENUES FROM CONTRACTS WITH CUSTOMERS

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

REVENUES FROM CONTRACTS WITH CUSTOMERS

Summary of Accounting Policies on Revenue Recognition

Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.

Performance Obligations

The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.

Significant Estimates

Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.

The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.

The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.

The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.

Contract Assets and Liabilities

Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet.

Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.

The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2025:




Dollars in thousands	Total
Contract Asset
Contract asset, January 1, 2025	$	6,146
Transferred to trade receivables from contract asset included in beginning of the year contract asset	$	(6,146)

Contract asset, net of transferred to trade receivables on contracts during the period	$	4,928
Contract asset, September 30, 2025	$	4,928

Contract Liability
Contract liability, January 1, 2025	$	19,669
Recognition of revenue included in beginning of year contract liability	$	(8,452)

Contract liability, net of revenue recognized on contracts during the period	$	11,008
Foreign currency translation	$	123
Contract liability, September 30, 2025	$	22,348

As of September 30, 2025, the short-term portion of the contract liability of $11.3 million, representing 51% of unsatisfied or partially unsatisfied performance obligations, is expected to be recognized as revenue within 12 months and is included in current liabilities in the consolidated balance sheet. The long-term portion of $11.0 million, representing the remaining balance to be recognized thereafter, is included in other liabilities in the consolidated balance sheet.

Shipping and Handling Fees

The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.

Product Warranties

Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.

Taxes Collected from Customers

The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.

Disaggregated Revenue

The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2025 and 2024 (dollar amounts in thousands):


	Three Months Ended September 30, 2025		Three Months Ended September 30, 2024		Nine Months Ended September 30, 2025		Nine Months Ended September 30, 2024
Neurosurgery	$	201,563	$	175,956	$	601,466	$	583,726
Instruments	50,151		54,238		154,181		153,148
ENT	40,869		40,588		121,557		92,103
Total Codman Specialty Surgical	292,583		270,782		877,204		828,977

Wound Reconstruction and Care	83,988		80,460		243,514		249,032
Private Label	25,491		29,592		79,602		89,872
Total Tissue Technologies	109,479		110,052		323,116		338,904
Total revenue	$	402,062	$	380,834	$	1,200,320	$	1,167,881

See Note 15. Segment and Geographic Information, for details of revenues based on the location of the customer.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

BASIS OF PRESENTATION (Policies)	9 Months Ended
BASIS OF PRESENTATION (Policies)	Sep. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION General The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise. In the opinion of management, the September 30, 2025 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K. The consolidated balance sheet as of December 31, 2024 was derived from audited financial statements, but does not include all disclosures required by GAAP. Operating results for the three and nine-month period ended September 30, 2025 are not necessarily indicative of the results to be expected for the entire year. The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the unaudited condensed consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. The amendments should be applied on a prospective basis. Retrospective application to all prior periods presented in the financial statements is permitted. The Company will adopt ASU 2023-09 for the annual period ending on December 31, 2025 on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), and in January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (“ASU 2025-01”). ASU 2024-03 requires additional disclosure of the nature of expenses included in the income statement. The standard requires disclosures about specific types of expenses included in the expense captions presented in the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its disclosures. In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”), which removes all references to software development project stages and requires entities to start capitalizing software costs when both of the following occur: (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. This ASU is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted as of the beginning of a fiscal year. The amendments may be applied prospectively, retrospectively, or via a modified prospective transition method. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements. There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company’s financial position, results of operations, or cash flows.
Cash and cash equivalents	Cash and cash equivalents The Company had cash and cash equivalents, primarily consisting of cash on-hand, as well as time deposits with original maturities of three months or less and money market funds, which are highly liquid and readily convertible to cash, totaling approximately $232.2 million and $246.4 million at September 30, 2025 and December 31, 2024, respectively.
Short-term investments	Short-term investments The Company had short-term investments, primarily consisting of time deposits with original maturities between three months and one year, totaling approximately $35.7 million and $27.2 million at September 30, 2025 and December 31, 2024, respectively. The short-term investments are valued based on Level 1 measurements in the fair value hierarchy.
Employee termination benefits	Employee termination benefits The Company does not have a written severance plan but has a history of providing benefits for employees in the case of involuntary termination. In situations outside the U.S., there are minimum statutory termination benefits requirements by country that must be paid to the affected employees. The Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In situations where the Company pays out termination benefits in excess of statutory minimum amounts based on management’s discretion, the Company records these termination costs once communication is made to the affected employees. The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met.
Summary of Accounting Policies on Revenue Recognition and Shipping and Handling Fees	Summary of Accounting Policies on Revenue Recognition Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services. Performance Obligations The Company’s performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers. Significant Estimates Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company’s strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant. The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract. The Company’s return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days. The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers. Contract Assets and Liabilities Revenues recognized from the Company’s private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet. Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability. Shipping and Handling Fees The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties	Product Warranties Certain of the Company’s medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers	Taxes Collected from Customers The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.

- Definition

Disclosure of accounting policy for investment in financial asset.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-17

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-19

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (e)
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

TREASURY STOCK (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2025	Dec. 31, 2024	Jul. 18, 2023
Class of Stock [Line Items]
Treasury stock outstanding (in shares)	14,416	14,445
Treasury stock	$ 690,025	$ 691,411
Treasury stock, average cost per share (in dollars per share)	$ 47.86	$ 47.86
Accelerated share repurchase program, receipt (payment)		$ 50,000
Accelerated share repurchases, shares received at inception (in shares)		1,300
Accelerated share repurchases, percentage of expected total repurchased		70.00%
Accelerated share repurchases, additional shares received (in shares)		400
2023 Share Repurchase Program
Class of Stock [Line Items]
Stock repurchase program, authorized amount			$ 225,000
Remaining amount under share repurchase	$ 50,000

ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2025 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
(Loss) gain reclassified from AOCI	$ (23,233)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
(Loss) gain reclassified from AOCI	(30,742)
Other income \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
(Loss) gain reclassified from AOCI	(35,700)
Cost of sales \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
(Loss) gain reclassified from AOCI	(300)
Interest income \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
(Loss) gain reclassified from AOCI	$ 12,800

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

+ Details